A mule named Juancito at work on the Mitre Peninsula, in Tierra del Fuego, Argentina. Photo: Dario u, public domain, via Wikimedia Commons

Mules are renowned worldwide for their outstanding muscular endurance, but what gives them this ability to outshine their horse and donkey parents?

Hybrid vigor has long been recognised and widely exploited in animal and plant breeding programs to enhance the productive traits of hybrid progeny from two breeds or species.

However, its underlying genetic mechanisms remain enigmatic.

Researchers from Northwest A&F University in Yangling, China, set out to understand more about the molecular mechanisms at work in mules that provide this superior muscular endurance.

Their genetic testing of samples from crosses between donkeys and horses mapped a total of 68 genes in the muscle contraction pathway, eight of which were found to be significantly enriched in mules.

In the hybrid individuals and their parents, one of these enriched genes, TNNC2, was mainly expressed in the fast skeletal muscle. Its expression level was found to be two times higher in the mule than in the horse.

They said their work, in which muscle, brain, and skin samples from mules, hinnies and their parents were tested, revealed significant differences between mules and hinnies, as well as differences between mules and both of their parents.

Apart from skeletal muscle tissue, which is the main difference which separates mules from hinnies and their parents, there are also clear differences between these animals in both the brain and skin.

The findings, they say, provide new insights into the genetic mechanism underlying hybrid vigor in mules.

The work could provide the basis for future studies of the genetic and molecular mechanism of hybrid vigor in donkeys and horses.

Gao, S.; Nanaei, H.A.; Wei, B.; Wang, Y.; Wang, X.; Li, Z.; Dai, X.; Wang, Z.; Jiang, Y.; Shao, J. Comparative Transcriptome Profiling Analysis Uncovers Novel Heterosis-Related Candidate Genes Associated with Muscular Endurance in Mules. Animals 2020, 10, 980.

The study, published under a Creative Commons License, can be read here.

Continued here:
What gives the mighty mule its endurance? Researchers investigate - Horsetalk

Recommendation and review posted by Bethany Smith

Editor's note: This is a feature from the Waynesboro Area Gala Cancer Auction Committee that shares a community member's fight against cancer. The articles were in advance of the 2020 auction, which has been canceled because of the COVID-19 pandemic.

Listen to your body. If its telling you somethings just not right, pay attention, Cindy Smith advises. A year ago, February 2019, her symptoms began. They might well have indicated irritable bowel or acid reflux, but neither scenario fit how she was feeling. By March she finally couldnt ignore the messages her body was sending her. When the sharp abdominal pains that at first occurred only briefly in the morning hit her midafternoon, she gave in and consulted gastroentrologist Andrew Lininger at WellSpan Health in Waynesboro. Within less than 24 hours, he called with the results of her CT scan that revealed a golf ball-sized growth in her abdomen. The colonoscopy that followed was unsuccessful because of a bowel blockage and within the week Cindy was meeting with Dr. Joshua Kesterson at Hershey Medical center. My doctors were wonderful, Cindy shared. I cant believe how quickly they acted and how compassionate they were.

On March 21, 2019 surgery performed at Hershey successfully removed Cindys ovaries, the large tumor and a few much smaller ones from her diaphragm everything Dr. Kesterson was able to find. Two weeks later, April 3, the diagnosis was confirmed stage three ovarian cancer that had spread to the area between her bladder and colon. Cindy was stunned. As she recalls the scene, When the doctor started explaining things he sounded like the teacher on the Charlie Brown cartoons Wa wa, wa wa, wa wa. It was unreal. I couldnt comprehend it was really happening. Id been so healthy my whole life. How? How did this happen? I couldnt make sense of it.

April 24 began a series of six three-treatment sessions, a total of 16 over the next five months. One of the repeated treatments took six hours and another lasted eight. Cindy opted for the most aggressive chemo that involved the insertion of two ports one on the front of her shoulder feeding directly into her blood stream and another on her stomach feeding directly into her abdominal cavity. The second was notorious for being very intense and painful, flooding the entire abdominal area with drugs. Most patients were able to endure less than half of the bag of medication, but Cindy quickly earned the handle of Rock Star by taking on the entire dosage with her worst discomfort during the infusion being an uncomfortable distention of her stomach. Three days later, when the steroids and anti-nausea medication wore off she crashed. I spent all of those months in a recliner totally exhausted, no appetite or taste buds to tolerate food. I lost 30 pounds. Sometimes I tried to do small chores in the kitchen, but twice I had to sit down, call for my husband Alan, and actually pass out with my head resting on the table. For the two days needed to complete each of her sessions at Hershey, Alan had a recliner delivered to Cindys sister Tamis house in Hummelstown just five miles from Hershey where they stayed along with their faithful dogs, Sofi and Gracie. The gauntlet finally ended on Aug. 14.

On Sept. 11 following her rebound to strength after the final treatment, CT scans and a CA125 blood test that checks for cancer markers revealed that Cindy was cancer free. Genetic testing that followed was good news for her daughters Tracye and Mandy because the strain isnt passed on, but not so good for Cindy. Her cancer is notorious for recurring and requires significant post treatment to discourage that. Maintenance therapy demands constant monitoring to achieve the proper balance that keeps the cancer at bay but doesnt deplete her hemoglobin and platelet counts.

Still, after all those months she was starting to feel like Cindy again sleeping in a real bed and taking a trip to the beach. But then her counts dropped so low, some essentially zero, that she was hospitalized for a few days. After transfusions and medication, she bounced back as her doctor made adjustments to find the right dosage. The newest and to date most effective maintenance drug for Cindys condition is called Zejula and fortunately she has been approved to receive it at no cost - a type of clinical trial situation. She recently successfully staved off a case of bronchial flu and is adjusting to her new, curlier hair. Her last CA125 blood test was excellent. A reading of 35 is indicative of no significant cancer and Cindys was 10. Lots of fingers are crossed that this continues.

As effusive as Cindys praise is for her doctors, the strides in treatment options and the loving support of family and friends, she credits her faith for being her mainstay through her ordeal. From the minute I got the diagnosis until this very day Ive handed my burden over to God. I trusted his hands and not my own strength. Ive never asked Why me? and am struck time after time with how blessed Ive been and how much more other people suffer. She continued, My whole perspective on life has changed. Little things like slow traffic or other minor inconveniences just dont upset me anymore. Not after this.

Cindys attitude, fortitude and spirit are an inspiration to others facing similar struggles. Since cancer has invaded her body she appreciates the unique burden she shares with other cancer victims. Its a constant battle, one that feels endless. Each checkup resurrects the fear that only an "all clear" result can allay. One of her doctors describes the ongoing follow-up as an umbilical cord keeping hope and reassurance alive. Cindy couldnt agree more.

Cancer touches an enormous number of individuals. Research and support for its victims need to continue until a cure is finally found. The Waynesboro Area Gala Cancer Auction has been highly successful in raising funds to sustain this cause for the past 38 years. Reluctantly, the auction committee has determined that the best course of action, given the ongoing circumstances and uncertainty associated with the coronavirus epidemic, is to cancel this years 39th auction that had been rescheduled for July 25. Please visit their website http://www.wagca.org for further details or to make a contribution to the cause. All monetary donations will still be distributed to area organizations this year.

Visit link:
Smith shares story of her battle with cancer - Waynesboro Record Herald

Recommendation and review posted by Bethany Smith

Adroit Market Research presents an updated and Latest Study on Predictive Genetic Testing Market 2020-2025. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market. The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Predictive Genetic Testing market during the forecast period (2020-2025).

Get sample copy of Predictive Genetic Testing Market [emailprotected] https://www.adroitmarketresearch.com/contacts/request-sample/1276

The report on the global Predictive Genetic Testing market also includes an in-depth analysis of the competitive landscape. It analyses key marketing and promotional strategies that are being adopted by key companies in the market. It also takes into account the existing development, historical events, and latest trends to provide the readers with a detailed understanding of the strategies adopted by leading companies. The market report mentions all factors and events impacting the growth of the market, such as mergers, acquisitions, joint ventures, strategic alliances, takeovers, and others. It also studies the overall intensity of the competition prevailing in the global Predictive Genetic Testing market.

Top Leading Key Players are:

Agilent, Technologies, Inc., BGI Genomics, F.Hoffman-La Roche Ltd., Genes In Life., Invitae Corporation, Illumina, Inc., 23andMe, Myriad Genetics, Inc., Pathway Genomics and Thermo Fisher Scientific, Inc.

Read complete report with TOC at: https://www.adroitmarketresearch.com/industry-reports/predictive-genetic-testing-market

Predictive Genetic Testing industry report also presents detailed insights into the regulatory framework of the global market. The Predictive Genetic Testing market report presents details regarding the key rules, regulations, plans, and policies in the market, which can influence several decisions and can have a significant impact on markets future growth prospects. It provides overview with growth analysis and historical & futuristic cost, revenue and demand. The research analysts provide an elaborate description of the value chain and its distributor analysis. The study meticulously unveils the market and contains substantial details about the projections with respect to industry, remuneration forecast, sales graph, and growth prospects over the forecast timeline.

Global Predictive Genetic Testing market is geographically segmented into Asia Pacific, the Middle East and Africa, Europe, Latin America, and North America. Amongst these, North America is anticipated to procure maximum share in the global Predictive Genetic Testing market revenue during the forecast period. This is because of the increasing adoption of Predictive Genetic Testing in several countries in the region. Asia Pacific, on the other hand, is likely to witness the highest market growth in the coming years. Persistent investments by public and private vendors for enhancing technologies of the market are expected to cause this growth.

Global Predictive Genetic Testing Market research report, besides ample understanding shared in the previous sections, the report also presents this comprehensive research report gauges for decisive conclusions concerning growth factors and determinants, eventually influencing holistic growth and lucrative business models in Global Predictive Genetic Testing Market. The report on this target market is a judicious compilation of in-depth and professional marketing cues that are crucially vital in delegating profit driven business decisions. Apart from these elaborate market specific information suggesting current market scenario, this market intelligence report also includes veritable insights on growth stimulating factors as well as cut throat competition amongst market players, based on which report readers can orchestrate growth specific decisions to harbor incremental growth in the target Global Predictive Genetic Testing Market.

Do You Have Any Query Or Specific Requirement? Ask to Our Industry Expert @ https://www.adroitmarketresearch.com/contacts/enquiry-before-buying/1276

About Us :

Adroit Market Research is an India-based business analytics and consulting company. Our target audience is a wide range of corporations, manufacturing companies, product/technology development institutions and industry associations that require understanding of a markets size, key trends, participants and future outlook of an industry. We intend to become our clients knowledge partner and provide them with valuable market insights to help create opportunities that increase their revenues. We follow a code Explore, Learn and Transform. At our core, we are curious people who love to identify and understand industry patterns, create an insightful study around our findings and churn out money-making roadmaps.

Contact Us :

Ryan JohnsonAccount Manager Global3131 McKinney Ave Ste 600, Dallas,TX 75204, U.S.APhone No.: USA: +1 972-362 -8199 / +91 9665341414

Follow this link:
Global Predictive Genetic Testing Market 2020: In-depth Study, Production Demand, Growth Strategies, Opportunities and Development Overview till 2025...

Recommendation and review posted by Bethany Smith

Trusted Business Insights answers what are the scenarios for growth and recovery and whether there will be any lasting structural impact from the unfolding crisis for the Genomics market.

Trusted Business Insights presents an updated and Latest Study on Genomics Market 2019-2026. The report contains market predictions related to market size, revenue, production, CAGR, Consumption, gross margin, price, and other substantial factors. While emphasizing the key driving and restraining forces for this market, the report also offers a complete study of the future trends and developments of the market.The report further elaborates on the micro and macroeconomic aspects including the socio-political landscape that is anticipated to shape the demand of the Genomics market during the forecast period (2019-2029).It also examines the role of the leading market players involved in the industry including their corporate overview, financial summary, and SWOT analysis.

Get Sample Copy of this Report @ Genomics Market Size, Share, Growth, Market Research and Industry Forecast Report, 2027 (Includes Business Impact of COVID-19)

Industry Insights, Market Size, CAGR, High-Level Analysis: Genomics Market

The global genomics market size was estimated at USD 17.2 billion in 2019 and is anticipated to expand at a CAGR of 7.7% over the forecast period. Noninvasive cancer screening-based research is one of the major factors playing a pivotal role in reshaping the genomics industry. Researchers from diverse areas of expertise are engaged in the development and establishment of clinical uses for gene-based liquid biopsy tests.Liquid biopsy solutions identify cancer-causing DNA mutations thus enabling early detection of cancer. Several companies have begun leveraging on genomics for the development of DNA liquid biopsy tests in order to detect cancer at early stage. Increasing applications of genomics in medicine has gained attention from military organizations, resulting in a significant increase in adoption of genetic testing in their healthcare systems. Military practitioners are implementing Carrier Screening for Genetic Conditions guidelines, which recommends Spinal Muscular Atrophy (SMA) screening in pregnant women.

Implementation of human genomics studies across public health programs such as population screening and consumer wellness programs are expected to create lucrative opportunities for the market. These programs are primarily targeted at optimizing preventive care for common chronic diseases such as cancer and heart disease.Traditional genome editing technologies are time-consuming, inefficient, and labor-intensive and have a limited capacity of maintaining pace with the fast-progressing genome modification era. However, advent of CRISPR/Cas9 nuclease, ZFN, and TALEN is set to address these challenges by facilitating easy and precise genome editing.Clinical healthcare is being considered as a gateway for introducing new sequencing technologies for U.S. residents. This trend is propelled by healthcare giants focusing on providing medical genomics across clinical patient care delivery. Also, newly developed gene editing technologies can control and potentially cure specific diseases via detection of underlying mutations in an individual. Thus, innovations in the medical genomics industry are expected to offer profitable opportunities for the market in the near future.Application andTechnology Insights of Genomics Market

Functional genomics is expected to be the largest revenue generating segment by 2027 owing to the generation of large amount of sequencing data. Introduction of high-throughput technologies employed in gene and protein studies has contributed to the segment growth. Advancements in the genomics industry range from studying individual genes to complete genomes and proteomes within a comparatively shorter time durations, which is another factor driving the segment growth.Investigating communication and response in individual targets within the molecular networks has offered useful insights regarding biological functions at a cellular level. Pathway analysis has emerged as a pivotal aspect to strengthen life sciences research along with a fundamental understanding of molecular and cellular biology targeted toward drug development. Thus, the pathway analysis approach is set to gain significant traction post the emergence of personalized therapies and genomics.Integration of genomics in the field of personalized therapy enables an in-depth analysis of navigating signaling pathways and disease networks. This further aids in addressing challenges associated with the development of therapeutics and genetic assays. Various biological resource types including gene ontology, gene annotation databases, and pathway databases can be effectively employed for pathway-based analysis.Deliverable InsightsThere is an increase in the number of demonstrations pertaining to miniaturized instruments targeted toward genomics applications in recent years. These instruments are designed to offer enhanced specificity, sensitivity, and automated features as compared to conventional instruments.However, the development of microfabrication technology and integrated microfluidic genomics systems is now aimed at the development of point-of-care devices. Increasing use of impedimetric detection is one of the promising techniques for the instruments in the market. Moreover, companies such as Formulatrix, Inc. are introducing innovative instruments that help researchers prepare and process samples before subjecting them to analysis.Increasing adoption of cloud-based solutions for robust and effective management of parallelization along with distribution of input data and user code on a large number of computer nodes is expected to propel the software solutions sector. This is anticipated to further contribute to the segment growth.Cloud computing offers a very prominent advantage of performing tasks in different parallel computing nodes along with the processors, which results in a significant reduction in waiting time. Integration of cloud computing solutions in processing NGS related data is expected to have a significant impact on the genomics market growth.End-use InsightsA steep decline in sequencing costs coupled with technological enhancements in informatics, genetic solutions are now widely used across various sectors ranging from small labs to clinical settings. Key end-use segments consist of pharmaceutical and biotechnology companies, hospitals and clinics, academic and government institutes, clinical and research laboratories, and other end users.Among these, the pharmaceutical and biotechnology companies segment is expected to dominate the global market throughout the forecast period owing to increasing number of genetic research studies. These are chiefly aimed at the development of efficacious drugs with fewer side effects and improving drug discovery process. This is also attributed to expanding penetration of genomics across diseases associated with immune system, central nervous system, and cardiovascular system.

Moreover, biotechnology companies are effectively employing gene-editing tools to address challenges pertaining to personalized treatment of patients through development of genetically engineered and recombinant products. Other end users include agriculture research institutes, direct-to-consumers (DTC), and forensic centers. The others segment is anticipated to witness profitable growth owing to significant demand for DTC among consumers, government, and genomics companies.

Regional Insights of Genomics Market

North America is anticipated to emerge as the dominant region in the market owing to rising patient awareness, substantial investments in research by government organizations, and advanced healthcare infrastructure. Changing regulations for usage and reimbursement are expected to fuel the adoption of genetic tests in this region.Presence of key players such as Bio-Rad Laboratories, Inc.; Cepheid, Inc.; Agilent Technologies; and Danaher Corporation have also contributed to the revenue generated by this region. Whereas, companies such as Illumina, Genomic Health, and Bluebird Bio that are operating at the forefront for revolutionizing the genomics industry, are also headquartered in U.S. These companies serve as pioneers in the fields of genetic sequencing, genetic diagnostics, and gene therapy respectively.Asia Pacific is expected to witness the fastest growth in the coming years owing to increasing adoption and awareness for latest genomics technologies in the emerging countries of this region. These technologies are targeted toward detection, treatment, and prognosis of genetic disorders. China is playing a pivotal role in the regional market growth by initiatives such as introduction of the Precision Medicine Initiative (PMI) for the use of genomics in healthcare in 2017.

Market Share Insights of Genomics Market

Major players include F. Hoffmann-La Roche Ltd..; Agilent Technologies, Thermo Fisher Scientific, Inc.; Bio-Rad Laboratories, Inc.; 23andMe, Inc.; Illumina, Inc.; Myriad Genetics, Inc.; Foundation Medicine, Inc.; Danaher; Pacific Biosciences; Oxford Nanopore Technologies; and BGI.In June 2019, BGI partnered with Eluthia, a Germany-based biotechnology company, for the development and commercialization of reproductive genetic tests across Germany. Such alliances are set to intensify the market competition in the near future.

Segmentations, Sub Segmentations, CAGR, & High-Level Analysis overview of Genomics Market Research ReportThis report forecasts revenue growth at global, regional, and country levels and provides an analysis on the latest industry trends and opportunities in each of the sub-segments from 2019 to 2030. For the purpose of this report, this market research report has segmented the global genomics market report on the basis of application and technology, deliverables, end use, and region:

Deliverable Outlook (Revenue, USD Million, 2019 2030)

Products

Instruments & Software

Consumables & Reagents

Services

Core Genomics Services

NGS-based Services

Biomarker Translation Services

Computational Services

Others

Application & Technology Outlook (Revenue, USD Million, 2019 2030)

Functional Genomics

Transfection

Real-time PCR

RNA interference

Mutational analysis

SNP analysis

Microarray analysis

Epigenetics

Bisulfite sequencing

Chromatin immunoprecipitation-sequencing (ChIP & ChIP-Seq)

Methylated DNA immunoprecipitation (MeDIP)

High resolution melt (HRM)

Chromatin accessibility assays

Microarray analysis

Pathway Analysis

Bead-based analysis

Microarray analysis

Real-time PCR

Proteomics tools (2-D PAGE; yeast 2-hybrid studies)

Biomarker Discovery

Mass spectrometry

Real-time PCR

Microarray analysis

Statistical analysis

Bioinformatics

DNA sequencing

Others

End-use Outlook (Revenue, USD Million, 2019 2030)

Clinical & Research Laboratories

Academic & Government Institutes

Hospitals & Clinics

Pharmaceutical & Biotechnology Companies

Other End Users

Quick Read Table of Contents of this Report @ Genomics Market Size, Share, Growth, Market Research and Industry Forecast Report, 2027 (Includes Business Impact of COVID-19)

Trusted Business InsightsShelly ArnoldMedia & Marketing ExecutiveEmail Me For Any ClarificationsConnect on LinkedInClick to follow Trusted Business Insights LinkedIn for Market Data and Updates.US: +1 646 568 9797UK: +44 330 808 0580

See the original post here:
Genomics Market 2020: Global Industry Analysis By Size, Share, Growth, Trends And Forecast To 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

Newswise NEW YORK, June 1, 2020 The Cancer Research Institute (CRI), a nonprofit organization dedicated since 1953 to saving more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer, announced today a series of public education and awareness offerings during its eighth annual Cancer Immunotherapy Month in June. The multimedia campaign aims to reach more than 5 million people globally to increase awareness of cancer immunotherapy (also known as immuno-oncology), clinical trials, and the urgent need for more funding to support lifesaving immunotherapy research.

Decades of scientific research on the immune system and its response to cancer have yielded a foundation for new treatments that can significantly extend or save lives for subsets of people with cancer who receive immunotherapy alone or in combination with other types of treatment, said Jill ODonnell-Tormey, Ph.D., CEO and director of scientific affairs at CRI. More research is needed to extend the benefits of immunotherapy to all cancer patients, and our goal is to raise awareness of the critical role patients, caregivers, advocates, scientists, and donors who support their research play in advancing immuno-oncology breakthroughs.

Over the past ten years, the FDA has approved immunotherapies to treat more than 20 types of cancer as well as cancers with a specific genetic mutation. This includes approvals for front-line therapy, where immunotherapy is given as the first course of treatment instead of conventional chemotherapy or radiation. Immunotherapy has also been shown to work synergistically with these and other treatments, offering more options for patients.

Cancer Immunotherapy Month aims to bring exciting advances like these into focus and to provide the public, including cancer patients and their caregivers, with trusted information to help them make the most informed treatment decisions in consultation with their medical team.

Important highlights of Cancer Immunotherapy Month include:

Im the Answer to Cancer Immunotherapy Patient StoriesEach week in June, CRI will featurevideo stories of patientssharing their cancer immunotherapy journeys, from diagnosis to treatment to living beyond treatment. Featured cancer types include esophageal, kidney, lung, and oral cancer.

Wear White for a Future Immune to CancerOn Friday, June 12,CRI invites the world to Wear White for a Future #Immune2Cancer to help raise awarenessabout the lifesaving potential of immunotherapy through the community-building power of social media. Getting involved is simple: wear white, snap and share a selfie on Twitter or Instagram, and use the hashtag #Immune2Cancer.

Live Stream Event: COVID-19 and Cancer Immunotherapy ResearchOn Thursday, June 18, at 3pm EDT, CRI immunotherapy experts Drs. Carl June, Miriam Merad, and E. John Wherry will join STAT news senior medical writer, Matthew Herper, for a livestream broadcast discussing how cancer immunotherapy research is aiding global efforts to treat COVID-19 patients and prevent future outbreaks. The discussion will be followed with a live Q&A session. Register at cancerresearch.org/covid-19-livestream.

Live Webinar Cancer Immunotherapy and You: Understanding Genomics and Genetic TestingOn Wednesday, June 24, at 12pm EDT, CRI will host a free, live webinar featuring Drs. Corrie Painter and Eliezer Van Allen of the Broad Institute of MIT and Harvard, who will discuss how genetic testing is helping inform cancer treatment decisions and how scientists are working to tap the full potential of genome-based medicine, followed by their answers to questions submitted by viewers. Register atcancerresearch.org/webinars.

Other Awareness, Educational, and Fundraising ActivitiesThroughout June, CRI will also provide daily immunotherapy highlights from the ASCO and AACR virtual meetings, share a series of 30 Outlooks from CRI scientists, patient community members, and donors about their vision for the future of cancer treatment, and offer an interactive cancer immunotherapy quiz. Cancer Immunotherapy Month activity will be shared across social media with the hashtag #CIM20. Finally, through June 30, all donations to CRI up to the first $300,000 will be matched dollar-for-dollar, helping to fuel more discovery to save more lives.

The Cancer Research Institute would like to thank the following generous sponsors of the eighth annual Cancer Immunotherapy Month:

# # #

About the Cancer Research Institute The Cancer Research Institute (CRI), established in 1953, is the worlds leading nonprofit organization dedicated exclusively to saving more lives by fueling the discovery and development of powerful immunotherapies for all types of cancer. Guided by a world-renowned Scientific Advisory Council that includes four Nobel laureates and 26 members of the National Academy of Sciences, CRI has invested $420 million in support of research conducted by immunologists and tumor immunologists at the worlds leading medical centers and universities, and has contributed to many of the key scientific advances that demonstrate the potential for immunotherapy to change the face of cancer treatment. To learn more, go tocancerresearch.orgor to see the full roster of Cancer Immunotherapy Month programs, go tocancerresearch.org/june.

Cancer Immunotherapy Month hashtag: #CIM20Wear White Day hashtag: #Immune2Cancer

Read more here:
Eighth Annual Cancer Immunotherapy Month in June Celebrates Progress in Treatment and Advances in Research - Newswise

Recommendation and review posted by Bethany Smith

The global NGS-based RNA-seq Market was valued at USD 0.89 billion in 2016 and is projected to reach USD 4.65billion by 2025, growing at a CAGR of 20.17% from 2017 to 2025.

Next-generation sequencing (NGS), also known as high-throughput sequencing, is the term used to describe a number of different modern sequencing technologies. The increasing focus on Genetic studies and gene based therapeutic technologies is expected to boost the growth of the market in coming years.

The Final Report will cover the impact analysis of COVID-19 on this industry:

Download Sample of This Strategic Report:https://www.kennethresearch.com/sample-request-10008386

Sample Infographics:

Market Dynamics:1. Market Drivers1.1 Advantages of RNA-seq Over Microarray Technology1.2 Technological Advancements in RNA-seq Products1.3 Increasing Number of RNA-seq Grants1.4 Increasing Number of Research Activities Involving RNA-seq1.5 Rapid Growth in Precision Medicine

View Source Of Related Reports:

NGS-based RNA-seq MarketMicrobiome Sequencing Services MarketMycoplasma Testing MarketSingle-cell Analysis MarketDigital PCR and Real-time PCR (qPCR) MarketAnalytical Standards MarketProtein Expression MarketCell Based Assays MarketPreimplantation Genetic Testing Market-Cellular Health Screening/Health Testing Market

2. Market Restraints2.1 Lack of Skilled Professionals2.2 Standardization Concerns of RNA-seq in Diagnostic Testing

Market Segmentation:1. Global NGS-based RNA-seqMarket, by End User:1.1 Research Centers and Academic & Government Institutes1.2 Hospitals & Clinics1.3 Pharmaceutical & Biotechnology Companies1.4 Other End Users

2.Global NGS-based RNA-seqMarket, by Application:2.1 Expression Profiling Analysis2.2 Small RNA Sequencing2.3 De Novo Transcriptome Assembly2.4 Variant Calling and Transcriptome Epigenetics

3. Global NGS-based RNA-seqMarket, by Technology:3.1 Sequencing By Synthesis3.2 Ion Semiconductor Sequencing3.3 Single-Molecule Real-Time Sequencing3.4 Nanopore Sequencing

4. Global NGS-based RNA-seq Market, by Product and Services:4.1 Sample Preparation4.1.1 Sample Preparation, By Workflow Step4.1.1.1 Fragmentation, End Repair, and Size Selection4.1.1.2 Library Preparation and Target Enrichment4.1.1.3 Quality Control4.1.2 Sample Preparation, By Method4.1.2.1 Manual Sample Preparation4.1.2.2 Microfluidic Sample Preparation4.1.2.3 Robotic Liquid Handling Sample4.1.3 Sequencing Platforms and Consumables4.1.4 Sequencing Services4.1.5 Data Analysis, Storage, and Management

5. Global NGS-based RNA-seq Market, by Region:5.1 North America (U.S., Canada, Mexico)5.2 Europe (Germany, UK, France, Rest of Europe)5.3 Asia Pacific (China, India, Japan, Rest of Asia Pacific)5.4 Latin America (Brazil, Argentina, Rest of Latin America)5.5 Middle East & Africa

Competitive Landscape:The major players in the market are as follows:1. Illumina, Inc.2. Thermo Fisher Scientific Inc.3. Pacific Biosciences of California, Inc.4. Qaigen N.V.5. F. Hoffmann-La Roche AG6. Agilent Technologies, Inc.7. BGI (Beijing Genomics Institute)8. Oxford Nanopore Technologies, Ltd9. Perkinelmer, Inc.10. Eurofins Scientific11. Gatc Biotech AG12. Macrogen, Inc.These major players have adopted various organic as well as inorganic growth strategies such as mergers & acquisitions, new product launches, expansions, agreements, joint ventures, partnerships, and others to strengthen their position in this market.

Request For Full Report:https://www.kennethresearch.com/sample-request-10008386

RESEARCH METHODOLOGY OF VERIFIED MARKET INTELLIGENCE:Research study on the NGS-based RNA-seqMarketwas performed in five phases which include Secondary research, Primary research, subject matter expert advice, quality check and final review.The market data was analyzed and forecasted using market statistical and coherent models. Also market shares and key trends were taken into consideration while making the report. Apart from this, other data models include Vendor Positioning Grid, Market Time Line Analysis, Market Overview and Guide, Company Positioning Grid, Company Market Share Analysis, Standards of Measurement, Top to Bottom Analysis and Vendor Share Analysis.

To know more about the Research Methodology of Verified Market Intelligence and other aspects of the research study, kindly get in touch with our sales team.

About Kenneth Research:

Kenneth Research provides market research reports to different individuals, industries, associations and organizations with an aim of helping them to take prominent decisions. Our research library comprises of more than 10,000 research reports provided by more than 15 market research publishers across different industries. Our collection of market research solutions covers both macro level as well as micro level categories with relevant and suitable market research titles. As a global market research reselling firm, Kenneth Research provides significant analysis on various markets with pure business intelligence and consulting services on different industries across the globe. In addition to that, our internal research team always keep a track on the international and domestic market for any economic changes impacting the products demand, growth and opportunities for new and existing players.

Contact Us

Kenneth Research

Email:[emailprotected]

Phone: +1 313 462 0609

Originally posted here:
NGS-based RNA-seq Market By Business Function (Marketing and Sales, Legal, Finance, and Workforce Management), Component (Software and Services),...

Recommendation and review posted by Bethany Smith

Scientists and researchers around the world are working round the clock to fight the COVID-19 pandemic. Gene editing using CRISPR is one such recent study.

In 2019, Assistant Professor Stanley Qi and his team in the departments of bioengineering and chemical and systems biology at Stanford University began working on a technique called PAC-MAN to fight influenza. PAC-MAN stands for Prophylactic Antiviral CRISPR in human cells and uses the gene-editing tool called Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR) technology.

The research team didnt know then that their technique could be used in fighting the global pandemic like COVID-19. When the pandemic emerged in Jan, the team decided to use their PAC-MAN technology to fight it. In collaboration with a group led by Michael Connolly, a principal scientific engineering associate in the Biological Nanostructures Facility at Berkeley Labs Molecular Foundry, the researchers have been developing a system to deliver PAC-MAN into the cells of a patient since March. Their preprint paper was recently peer-reviewed and published in the journalCell.

Read Also: New link found between heart failure medicine and virus responsible for mono, some cancers

Like all CRISPR systems, PAC-MAN comprises of the virus-killing enzyme Cas13 and a strand of guide RNA. The guide RNA commands Cas13 to destroy specific nucleotide sequences in the coronaviruss genome, effectively neutralizing it and stopping its replication.

Every gene-editing tool needs an efficient delivery system to deliver them to the molecular or cellular level. According to Qi, their lab doesnt work on cellular delivery methods, and Connollys work on synthetic molecules called lipitoids at the Molecular Foundry came to their rescue. Lipitoids were first discovered 20 years ago by Connollys mentor Ron Zuckermann is a type of synthetic peptide mimic known as a peptoid. In the decades since the discovery, Connolly and Zuckermann have developed peptoid delivery molecules such as lipitoids.

Qi hopes to add his CRISPR-based COVID-19 therapy to the Molecular Foundrys growing body of lipitoid delivery systems. Their late April tests performed well. When packaged with coronavirus-targeting PAC-MAN, the system reduced the amount of synthetic SARS-CoV-2 in solution by more than 90%. The team is planning to conduct further tests in an animal model against live SARS Coronavirus-2.

Read Also: SARS-CoV-2 transmission does not fasten due to mutation, study says

If the tests prove successful, the team hopes to continue working with Connolly and his team to develop PAC-MAN/lipitoid therapies for SARS-CoV-2 and other coronaviruses. And also, explore options to scale up for a clinical trial.

The research is highly significant. It would be a powerful strategy to fight not just coronaviruses but possibly against new viral strains that can become a pandemic.

Do you want to publish on Apple News, Google News, and more? Join our writing community, improve your writing skills, and be read by hundreds of thousands around the world!

Source: Phys.org, Berkeley Lab

See the rest here:
A breakthrough in Gene Editing to help in the fight against COVID-19 - News Landed

Recommendation and review posted by Bethany Smith

Five years ago, we had only one treatment for sickle cell disease, a disease that should not be taken lightly.

This disease can be a pain-generating disease that actually affects all organs of the body. This can start at the heart, blood vessels, brain, joints, bones and also the lungs.

Sickle cell is due to a mutation of a tiny gene that leads to an unstable hemoglobin. The sickles in the hemoglobin, when stressed, deprive tissue from oxygen that can lead to what we call crisis.

Crisis starts with pain, but it can also lead to stroke, heart attack and limb loss. Sickle cell crisis is when the abnormal cell gets stuck in the small blood vessels.

Sickle cell disease affects approximately 100,000 people in the United States. For years, the only therapeutic option was Hydroxyurea. This drug has been in existence since 1984. We know that this drug works, since it has proved to be effective in increasing hemoglobin, reducing pain and acute chest syndrome.

This drug has also decreased the number of blood transfusions in patients who suffer from sickle cell disease. Unfortunately, Hydroxyurea is chemotherapy and requires close monitoring. This therapy works over time with each patient; therefore, not all patients will respond equally. Since Hydroxyurea was introduced, there has been a need for new treatments. For the past several years, more therapies have started to emerge.

The first notable drug that has been FDA approved in 2017, since Hydroxyurea, is L-glutamine (Endari). This drug works on the inflammatory part of the disease. It has also proved to decrease the number of pain crisis and lessen acute chest syndrome.

The second drug is Voxelotor. This drug is a once-daily pill that stabilizes the oxygenated hemoglobin. Trials have proved to make patients less anemic, but events are not necessarily less painful. More long-term studies are looking at this issue. This drug is available, and FDA approved, through an accelerated program.

The third drug is Crizanlizumab. This drug helps with the stickiness of the red blood cells against the sticky vessel wall. This is one of the detrimental aspects of this disease. A randomized study called SUSTAIN proved that this intravenous drug decreases the number of painful crisis. This drug was FDA approved through a breakthrough therapy program.

Lastly, there is gene therapy. This type of treatment consists of an auto stem cell transplant of a viral infected, anti-sticking hemoglobin. This therapy still requires chemotherapy to wipe out the bone marrow so that space can be made for the transplant. The results of this treatment have been very successful.

Many promising therapies are seeing the light and are changing the care of this complex disease so that patients with sickle cell disease can lead a semi-normal lifestyle.

Dr. Ziad Skaff is board certified in hematology and oncology. He serves as chief of staff of MUSC Health-Florence Medical Center and Medical Director of Oncology Services. Dr. Skaff is associated with MUSC Health Hematology & Oncology, located at 805 Pamplico Highway, Medical Pavilion A, Suite 315. To schedule an appointment, call 843-674-6460.

Read the original here:
Sickle cell treatment then and now - SCNow

Recommendation and review posted by Bethany Smith

Every week there are numerous scientific studies published. Heres a look at some of the more interesting ones.

Toxic Tau Proteins Spread in Alzheimers Patients Via Connected Neurons

Two abnormal proteins are associated with Alzheimers disease, beta-amyloid and tau. A study out of Lund University in Sweden and McGill University in Canada showed how toxic tau in the human brain in elderly individuals spreads by way of connected neurons. They also found that beta-amyloid facilitates the spread of toxic tau. The research was published in the journal Nature Communications.

Our research suggests that toxic tau may spread across different brain regions through direct neuronal connections, much like infectious diseases may spread to different cities through different transportation pathways, said lead author Jacob Vogel from McGill. The spread is restricted during normal aging, but in Alzheimers disease the spread may be facilitated by beta-amyloid, and likely leads to widespread neuronal death and eventually dementia.

Beta-amyloid forms plaques in the brain and tau forms tangles within brain cells. Toxic tau, in particular, has been linked to brain degeneration and cognitive symptoms. In general, beta-amyloid appears earlier in the disease with tau appearing later.

Our findings have implications for understanding the disease, but more importantly for the development of therapies against Alzheimers, which are directed against either beta-amyloid or tau, said Oskar Hansson, co-lead investigator of the study and professor of neurology at Lund. Specifically, the results suggest that therapies that limit uptake of tau into the neurons or transportation or excretion of tau, could limit disease progression.

Improving on Gene Therapy by Decreasing Immune Response to AAV

Biotech company Spark Therapeutics published research in the journal Nature Medicine showing that treatment with immunoglobulin G-degrading enzyme of Streptococcus pyogenes (IdeS0 caused fast and transient decrease of neutralizing anti-adeno-associated virus (AAV) antibodies and restored gene therapy efficacy in laboratory animals. The study was conducted by Spark, Genethon, the Centre de Recherche des Cordeliers (Inserm, Sorbonne Universite, Universite de Paris) and the National Centre for Scientific Research (CNRS) in France.

Biggest Risk Factors for Severe COVID-19 in UK

In a large cohort study published in The BMJ of COVID-19 patients in the UK, the biggest risk factors for severe disease or death were found to be age over 50, being male, obese, or having underlying heart, lung, liver and kidney disease. The study, which is still ongoing, recruited over 43,000 patients. The study essentially looked at data from a third of all COVID-19 patients admitted to hospitals in the UK between February 6 and April 19, 2020. Overall, the data confirms studies conducted in China, although obesity was not highlighted in the China data. The researchers believe that reduced lung function or obesity-related inflammation are the factors involved in increased disease severity or mortality in obese patients.

Warmer Temperatures Slow COVID-19A Little Bit

Researchers at Mount Auburn Hospital evaluated the impact of temperature, precipitation and UV index on COVID-19 cases in the U.S. during the spring of 2020. They found that while the rate of COVID-19 incidence decreases with warmer temperatures up to 52 degrees F, anything warmer than that does not decrease disease transmission all that much. Precipitation doesnt seem to have any effect and UV index helps a little bit. The bottom line, they say, is that their research supports what the Centers for Disease Control and Prevention (CDC) is saying, which is that although the pandemic might abate a little bit in the summer, it is expected to be worse in the fall and winter.

Antibodies Against Alzheimers Toxic Particles

Investigators at the University of Cambridge have identified a method to design an antibody that can seek out and attack the toxic particles that destroy healthy brain cells, such as in Alzheimers disease. These antibodies recognize amyloid-beta oligomers. They believe this could lead to new diagnostics or possible treatments for Alzheimers and other types of dementia.

Oligomers are difficult to detect, isolate, and study, said Francesco Aprile, the studys lead author. Our method allows the generation of antibody molecules able to target oligomers despite their heterogeneity, and we hope it could be a significant step towards new diagnostic approaches.

Physical Distancing, Masks and Eye Protection Help Prevent COVID-19

As has been suggested all along, the use of physical distancing, face masks and eye protection does appear, in a systematic review of the literature by researchers at McMaster University, to help prevent the transmission of COVID-19. The two meters (about six feet) physical distancing seems to prevent person-to-person transmission and face masks and eye protect decrease the risk of infection.

Although the direct evidence is limited, the use of masks in the community provides protection, and possibly N95 or similar respirators worn by health care workers suggest greater protection than other face masks, said Holger Schunemann, professor of the departments of health research methods, evidence, and impact, and medicine at McMaster. Availability and feasibility and other contextual factors will probably influence recommendations that organizations develop about their use. Eye protection may provide additional benefits.

The review was led by McMaster researchers, but also included a large, international collaboration of researchers, front-line and specialist clinicians, epidemiologists, patients, public health and health policy experts of published and unpublished studies in any language. They also evaluated direct evidence on COVID-19 and indirect evidence on other coronaviruses, such as the ones that cause SARS and MERS. Although there were no randomized control trials addressing the three coronaviruses (SARS, MERS and COVID-19), they found 44 relevant comparative studies in health care and community settings across 16 countries and six continents from inception to early May 2020. The study was published in The Lancet.

Read the original:
Research Roundup: How Tau Proteins Spread in Alzheimer's and More - BioSpace

Recommendation and review posted by Bethany Smith

SEATTLE and KING of PRUSSIA, Pa., June 2, 2020 /PRNewswire/ --Seattle Children's Research Institute, one of the top pediatric research institutions in the world, and global biotechnology leader CSL Behring announced a strategic alliance to develop stem cell gene therapies for primary immunodeficiency diseases.

Initially, the alliance will focus on the development of treatment options for patients with two rare, life-threatening primary immunodeficiency diseases -- Wiskott-Aldrich Syndrome and X-linked Agammaglobulinemia. These are two of more than 400 identified primary immunodeficiency diseases in which a part of the body's immune system is missing or functions improperly.

"CSL Behring will collaborate with Seattle Children's experts to apply our novel gene therapy technology to their research pipeline, with an aim to address unmet needs for people living with certain rare primary immunodeficiency diseases," said Bill Mezzanotte, MD, Executive Vice President, Head of Research and Development for CSL Behring. "Expanding our gene therapy portfolio into an area of immunology well known to CSL exemplifies how we are strategically growing our capabilities in this strategic scientific platform and are collaborating with world class institutions to access innovation with the potential to vastly improve patients' lives."

"Stem cell gene therapies that correct the genetic abnormality driving a child's disease will transform the therapeutic options for children with Wiskott-Aldrich Syndrome, X-Linked Agammaglobulinemia and other immunodeficiency diseases,"said David J. Rawlings, MD, director of the Center for Immunity and Immunotherapies and division chief of immunology at Seattle Children's, and a professor of pediatrics and immunology at the University of Washington School of Medicine."The collaboration with CSL Behring supports our longstanding research programs for pediatric immunodeficiency diseases and will accelerate this research toward clinical trials, helping get these innovations to the children who need them."

CSL Behring researchers, working with researchers from Seattle Children's Research Institute, will investigate applying the proprietary platform technologies, Select+ and Cytegrity, to several pre-clinical gene therapy programs. These technologies, which have broad applications in ex vivo stem cell gene therapy, are designed to address some of the major challenges associated with the commercialization of stem cell therapy, including the ability to manufacture consistent, high-quality products, and to improve engraftment, efficacy and tolerability.

Wiskott-Aldrich Syndrome (WAS) has an estimated incidence between one and 10 cases per million males worldwide, according to the National Institutes of Health. WAS patients' immune systems function abnormally, making them susceptible to infections. They also experience eczema, autoimmunity and difficulty forming blood clots, leaving them vulnerable to life threatening bleeding complications. Today the only knowncurefor WAS is a stem cell transplant, if a suitable donor can be found.

X-linked Agammaglobulinemia (XLA) is another rare primary immunodeficiency in which patients have low levels of immunoglobulins (also known as antibodies), which are key proteins made by the immune system to help fight infections. Like WAS, XLA affects males almost exclusively, although females can be genetic carriers of the condition. While no cure exists for XLA, the goal of treatment is to boost the immune system by replacing missing antibodies and preventing or aggressively treating infections that occur, according to the Immune Deficiency Foundation.

About Seattle Children's

Seattle Children's mission is to provide hope, care and cures to help every child live the healthiest and most fulfilling life possible. Together, Seattle Children's Hospital, Research Institute and Foundation deliver superior patient care, identify new discoveries and treatments through pediatric research, and raise funds to create better futures for patients.

Ranked as one of the top children's hospitals in the country by U.S. News & World Report, Seattle Children's serves as the pediatric and adolescent academic medical center for Washington, Alaska, Montana and Idaho the largest region of any children's hospital in the country. As one of the nation's top five pediatric research centers, Seattle Children's Research Institute is internationally recognized for its work in neurosciences, immunology, cancer, infectious disease, injury prevention and much more. Seattle Children's Hospital and Research Foundation works with the Seattle Children's Guild Association, the largest all-volunteer fundraising network for any hospital in the country, to gather community support and raise funds for uncompensated care and research. Join Seattle Children's bold initiative It Starts With Yes: The Campaign for Seattle Children's to transform children's health for generations to come.

For more information, visit seattlechildrens.org or follow us on Twitter, Facebook, Instagram or on our On the Pulse blog.

About CSL Behring

CSL Behring is a global biotherapeutics leader driven by its promise to save lives. Focused on serving patients' needs by using the latest technologies, we develop and deliver innovative therapies that are used to treat coagulation disorders, primary immune deficiencies, hereditary angioedema, inherited respiratory disease, and neurological disorders. The company's products are also used in cardiac surgery, burn treatment and to prevent hemolytic disease of the newborn. CSL Behring operates one of the world's largest plasma collection networks, CSL Plasma. The parent company, CSL Limited (ASX:CSL;USOTC:CSLLY), headquartered in Melbourne, Australia, employs more than 26,000 people, and delivers its life-saving therapies to people in more than 70 countries. For more information, visit http://www.cslbehring.com and for inspiring stories about the promise of biotechnology, visit Vita http://www.cslbehring.com/Vita.

See more here:
CSL Behring and Seattle Children's Research Institute to Advance Gene Therapy Treatments for Primary Immunodeficiency Diseases - The Delaware County...

Recommendation and review posted by Bethany Smith

The current coronavirus pandemic clearly illustrates how dangerous viral infections can become for us. Independent of the present situation, there are people whose bodies are defenseless against infections because their immune systems are unable to combat them - they suffer from immunodeficiency diseases such as ADA-SCID (adenosine deaminase severe combined immunodeficiency) or Wiskott-Aldrich syndrome. Prof. Dr. Alessandro Aiuti, a physician and research scientist based in Milan who works at the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) and at the Vita Salute San Raffaele University, is now being honored with the Else Krner Fresenius Prize for Medical Research 2020 for his groundbreaking successes in the development of gene therapies. The award is coupled to 2.5 million euros in prize money.

In the case of the rare immune disorder ADA-SCID, which exclusively afflicts young children and occurs about 15 times a year in Europe, a defective ADA gene within the genome disrupts lymphocyte development, leaving the young patient's body defenseless against infections. "Without effective therapy, the children rarely survive for more than 2 years because any infection can become perilous for them," Aiuti explains. Standard for this therapy is a bone marrow transplantation from a fully matched sibling. However, a suitable donor is available only for a minority of patients. "Meanwhile children with such a condition benefit from the advances we have made in the field of gene therapy. So far we have treated 36 children from 19 countries using the therapy we developed. In more than 80 percent of the cases, the treatment has had such an impact that no enzyme replacement therapy or transplantation is needed. This achievement has been made possible by the extraordinary effort and dedication of SR-Tiget researchers and clinical team throughout 25 years," Aiuti adds. All of the patients are still alive.

For these successes and his other work in the field of gene therapy, Alessandro Aiuti has now been honored with the Else Krner Fresenius Prize for Medical Research 2020 awarded by the Else Krner-Fresenius-Stiftung (EKFS) foundation. At 2.5 million euros, this award is one of the highest endowed prizes for medical research in the world. "Still young by comparison, this year the prize is being awarded for the third time. It honors research scientists for pioneering contributions in the areas of biomedical science. A major percentage of the prize money flows into the prizewinner's research and is supposed to contribute toward achieving further groundbreaking findings and medical breakthroughs in the future as well," emphasizes Prof. Dr. Michael Madeja, scientific director and member of the management board at EKFS.

The decision regarding the prize recipient was made by a ten-member international jury composed of renowned research scientists in the fields of genome editing and gene therapy along with delegates from the Scientific Commission at EKFS. Prof. Dr. Hildegard Bning, chairwoman of the jury and president of the European Society for Gene and Cell Therapy (ESGCT), substantiates the jury's decision: "Alessandro Aiuti is a truly outstanding physician and scientist. His work has decisively contributed to the development and successful treatment of rare, genetically caused disorders such as SCID. Thanks not least of all to the contributions he has made, even patients with other inheritable illnesses can presumably be treated successfully in the future."

After successful clinical trials, the gene therapy developed for ADA-SCID patients was approved as a pharmaceutical remedy in Europe. It is considered to be one of the key findings in the development of gene therapies worldwide. With this treatment certain blood stem cells (CD34+) are taken from the patient, then the cell DNA is modified. The cells are treated outside the body using a viral vector to accomplish this. The correct version of the gene for the ADA enzyme is introduced into the genome of the cells that were collected. The genetically modified cells are returned to the patient's bloodstream via intravenous infusion. A portion of the modified cells subsequently establish themselves in bone marrow again. The patient now has blood stem cells that function properly and produce lymphocytes to defend against infections - presumably on a life-long basis.

Alessandro Aiuti wants to utilize the prize money from EKFS to set the success story forth, to optimize the therapies further and map out the healing mechanisms involved in a better fashion. The scientist sees another major challenge in conveying the acquired knowledge beyond the successful gene therapies from Milan to as many other genetic disorders as possible. Alongside the therapy for ADA-SCID, the San Raffaele Telethon Institute for Gene Therapy has also developed gene therapies for four more hereditary diseases, among them the Wiskott-Aldrich syndrome and metachromatic leukodystrophy (MLD). To this day a total of more than 100 patients from 35 different countries have been treated.

Biography of Alessandro Aiuti

Alessandro Aiuti was born in Rome in 1966 and studied medicine there at Sapienza University. Following a stay at Harvard Medical School in Boston, Massachusetts in the USA, he received his doctorate in Human Biology in 1996 from Sapienza University. Since 1997 he has been active at the San Raffaele Scientific Institute in Milan, where he meanwhile also teaches as a professor at the Vita Salute San Raffaele University. He is furthermore Deputy Director of Clinical Research at the San Raffaele Telethon Institute for Gene Therapy and Head of the Pediatric Immunohematology Unit at San Raffaele Hospital.

Aiuti is the author of numerous and highly acclaimed publications. Over the course of his career he has received a number of prizes from national and international institutions. Aiuti is a member of the board of the European Society of Gene and Cell Therapy, and a member of the EMA Committee for Advanced Therapies since 2019.

The Else Krner Fresenius Prize for Medical Research

The international Else Krner Fresenius Prize for Medical Research came into existence in 2013 on the occasion of the 25th anniversary of Else Krner's death and is awarded in alternating fields of biomedical science. Endowed with 2.5 million euros, the prize is one of the most highly endowed medical research awards in the world. It honors and supports research scientists who have made significant scientific contributions in their fields and whose work can be expected to yield groundbreaking findings and medical breakthroughs in the future as well.

The Else Krner-Fresenius-Stiftung (EKFS) foundation - Advancing research. Helping people.

The Else Krner-Fresenius-Stiftung, a non-profit foundation, is dedicated to the funding of medical research and supports medical/humanitarian projects. The foundation was established in 1983 by entrepreneur Else Krner and appointed as her sole heir. EKFS receives virtually all of its income in dividends from the Fresenius healthcare group, in which the foundation is the majority shareholder. To date, the foundation has funded around 2,000 projects. With a current annual funding volume around 60 million euros the EKFS is one of the largest foundations for medicine in Germany. More information:www.ekfs.de.

The San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget)

Based in Milan, Italy, the San Raffaele-Telethon Institute for Gene Therapy (SR-Tiget) is a joint venture between the Ospedale San Raffaele and Fondazione Telethon. SR-Tiget was established in 1995 to perform research on gene transfer and cell transplantation and translate its results into clinical applications of gene and cell therapies for different genetic diseases. Over the years, the Institute has given a pioneering contribution to the field with relevant discoveries in vector design, gene transfer strategies, stem cell biology, identity and mechanism of action of innate immune cells. SR-Tiget has also established the resources and framework for translating these advances into novel experimental therapies and has implemented several successful gene therapy clinical trials for inherited immunodeficiencies, blood and storage disorders, which have already treated >115 patients and have led through collaboration with industrial partners to the filing and approval of novel advanced gene therapy medicines.

Fondazione Telethon

Fondazione Telethon is a non-profit organisation created in 1990 as a response to the appeals of a patient association group of stakeholders, who saw scientific research as the only real opportunity to effectively fight genetic diseases. Thanks to the funds raised through the television marathon, along with other initiatives and a network of partners and volunteers, Telethon finances the best scientific research on rare genetic diseases, evaluated and selected by independent internationally renowned experts, with the ultimate objective of making the treatments developed available to everyone who needs them. Throughout its 30 years of activity, Fondazione Telethon has invested more than EUR 528 million in funding more than 2.630 projects to study more than 570 diseases, involving over 1.600 scientists. Fondazione Telethon has made a significant contribution to the worldwide advancement of knowledge regarding rare genetic diseases and of academic research and drug development with a view to developing treatments. For more information, please visit:www.telethon.it

Issued by news aktuell/ots on behalf of Else Krner-Fresenius-Stiftung

More here:
Groundbreaking Gene Therapies for Hereditary Diseases / Alessandro Aiuti, a physician and research scientist from Milan, receives the Else Krner...

Recommendation and review posted by Bethany Smith

Much of the news has been focused on the novel coronavirus and the rush to develop vaccines and treatments for the disease it causes (called COVID-19). But what is happening with all the other companies not directly involved in COVID-19 research? And how is COVID-19 affecting their clinical trials and drug supplies?

To answer these questions, BioSpace looked at COVID-19s impact on each of the Hotbeds.

Biotech Bay, the bustling biotech industry around San Francisco in California, is home to lots of biopharma companies, many of whom are trying to keep business as close to usual while adapting to these unique times.

Check out the table below for the impacts that Biotech Bay companies are experiencing due to COVID-19.

(For information about what Biotech Bay companies have joined the fight against COVID-19 and how they are working towards vaccines and treatments, check out this article.)

The information in this table was up to date as of May 18, 2020.

4D Molecular Therapeutics

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Allakos, Inc.

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Ambys Medicines

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Apollomics, Inc.

Disease Focus:

Clinical Trial Impacts of COVID-19:

Arcus Biosciences

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Assembly Biosciences

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

BioMarin Pharmaceutical Inc.

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

BridgeBio

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

DNA Script

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Eurofins DiscoverX

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Exelixis, Inc.

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

FibroGen

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Global Blood Therapeutics

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Horizon Therapeutics

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Intabio

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Iovance Biotherapeutics

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

JOINN Biologics

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

Maze Therapeutics

Disease Focus:

Clinical Trial Impacts of COVID-19:

Drug Supply Impacts of COVID-19:

MyoKardia

Disease Focus:

Clinical Trial Impacts of COVID-19:

More:
How COVID-19 is Affecting Clinical Trials and Drug Supplies from Biotech Bay Companies - BioSpace

Recommendation and review posted by Bethany Smith

Prophecy Market Insights Gene Therapy market research report provides a comprehensive, 360-degree analysis of the targeted market which helps stakeholders to identify the opportunities as well as challenges. The research report study offers keen competitive landscape analysis including key development trends, accurate quantitative and in-depth commentary insights, market dynamics, and key regional development status forecast 2020-2029. It incorporates market evolution study, involving the current scenario, growth rate, and capacity inflation prospects, based on Porters Five Forces and DROT analyses.

Get Sample Copy of This Report @ https://www.prophecymarketinsights.com/market_insight/Insight/request-sample/39

An executive summary provides the markets definition, application, overview, classifications, product specifications, manufacturing processes; raw materials, and cost structures.

Market Dynamics offers drivers, restraints, challenges, trends, and opportunities of the Gene Therapy market

Segment Level Analysis in terms of types, product, geography, demography, etc. along with market size forecast

Regional and Country- level Analysis different geographical areas are studied deeply and an economical scenario has been offered to support new entrants, leading market players, and investors to regulate emerging economies. The top producers and consumers focus on production, product capacity, value, consumption, growth opportunity, and market share in these key regions, covering

The comprehensive list of Key Market Players along with their market overview, product protocol, key highlights, key financial issues, SWOT analysis, and business strategies. The report dedicatedly offers helpful solutions for players to increase their clients on a global scale and expand their favour significantly over the forecast period. The report also serves strategic decision-making solutions for the clients.

Competitive landscape Analysis provides mergers and acquisitions, collaborations along with new product launches, heat map analysis, and market presence and specificity analysis.

Segmentation Overview:

Gene TherapyMarket Key Companies:

GlaxoSmithKline plc, Bluebird Bio, Inc., Adaptimmune Therapeutics plc, Celgene Corporation, Shanghai Sunway Biotech Co. Ltd., Merck KGaA, Transgene SA, and OncoGenex Pharmaceuticals, Inc.

The Gene Therapy research study comprises 100+ market data Tables, Graphs & Figures, Pie Chat to understand detailed analysis of the market. The predictions estimated in the market report have been resulted in using proven research techniques, methodologies, and assumptions. This Gene Therapy market report states the market overview, historical data along with size, growth, share, demand, and revenue of the global industry.

Request [emailprotected] https://www.prophecymarketinsights.com/market_insight/Insight/request-discount/39

The study analyses the manufacturing and processing requirements, project funding, project cost, project economics, profit margins, predicted returns on investment, etc. This report is a must-read for investors, entrepreneurs, consultants, researchers, business strategists, and all those who have any kind of stake or are planning to foray into the Gene Therapy industry in any manner.

Key Questions Answered in Report:

Stakeholders Benefit:

About us:

Prophecy Market Insights is specialized market research, analytics, marketing/business strategy, and solutions that offers strategic and tactical support to clients for making well-informed business decisions and to identify and achieve high-value opportunities in the target business area. We also help our clients to address business challenges and provide the best possible solutions to overcome them and transform their business.

Contact Us:

Mr. Alex (Sales Manager)

Prophecy Market Insights

Phone: +1 860 531 2701

Email: [emailprotected]

See the rest here:
Strategic Analysis to Understand the Competitive Outlook of Gene Therapy Market - Cole of Duty

Recommendation and review posted by Bethany Smith

Facts & Factors (FnF),a leading market research company recently published a research report on Cell and Gene Therapy Consumables Market By Product Type (Kits & Buffers, Diagnostic Assay, Culture Medium, and Cryopreservation Media) and By Application/ Therapeutics (Cardiovascular, Urology, Dermatology, Critical Care, Respiratory, Endocrine & Metabolic, Neuroscience, Hematology & Oncology, Obstetrics, Immunology, and Gastroenterology): Global Industry Perspective, Comprehensive Analysis, and Forecast, 2018 2027 to its research database. This Cell and Gene Therapy Consumables Market report analyses the comprehensive overview of the market comprising an executive summary that covers core trends evolving in the market.

TheCell and Gene Therapy Consumables marketreport aims to enumerate market size and trends, which is accompanied and put in plain words with qualitative data. The Cell and Gene Therapy Consumables industry segmentation is carefully analyzed with an observation stage analyzing and the present and past situations. Considering the facts, the likely future situations and estimates for the future are developed. The cultural diversity has always been the main concern for any business. So, we have illustrated this through geographical analysis which makes it easy to understand the revenue flow through each region.

Some of Top Market Players Analysis Included in this Report:

Request an Exclusive Free Sample Report of Cell and Gene Therapy Consumables Market:https://www.fnfresearch.com/sample/cell-and-gene-therapy-consumables-market-by-product-107

Our Every Readily Available Free Sample Includes:

The Market Player Analysis based on some of below Factors:

The Cell and Gene Therapy Consumables industry report offers the analyzed data by bifurcating the Cell and Gene Therapy Consumables market on the basis of form and type of product or service, processing technology involved applications of the end-product, and others, including the geographical categorization of the market. The Cell and Gene Therapy Consumables market report also provides detailed information regarding specific business and financial terms, market strategies, expected market growth, and much more.

Make an Enquiry Before Purchase this Report@https://www.fnfresearch.com/inquiry/cell-and-gene-therapy-consumables-market-by-product-107

(You may enquire a report quote OR available discount offers to our sales team before purchase.)

The Cell and Gene Therapy Consumables market supports various industries, product manufacturers, organizations, vendors, and suppliers by opening doors for them with many opportunities to expand their business at the global and regional levels. Some of the major market holders at the global and regional levels are competing with one another and developing organizations in terms of sales, supply, manufacturing quality products, revenue generation, and providing satisfactory after-sales services to the clients.

The report study further includes an in-depth analysis of industry players market shares and provides an overview of leading players market position in the Cell and Gene Therapy Consumables sector. Key strategic developments in the Cell and Gene Therapy Consumables market competitive landscape such as acquisitions & mergers, inaugurations of different products and services, partnerships & joint ventures, MoU agreements, VC & funding activities, R&D activities, and geographic expansion among other noteworthy activities by key players of the Cell and Gene Therapy Consumables market are appropriately highlighted in the report.

Request Customized Copy of Report @https://www.fnfresearch.com/customization/cell-and-gene-therapy-consumables-market-by-product-107

(We customize your report according to your research need. Ask our sales team for report customization).

Available Customization Options:

The Cell and Gene Therapy Consumables Market can be customized to the country level or any other market segment. Besides this, Report understands that you may have your own business need, hence we also provide fully customized solutions to clients.

The Cell and Gene Therapy Consumables market report aims to enumerate market size and trends, which is accompanied and put in plain words with qualitative data. The Cell and Gene Therapy Consumables industry segmentation is carefully analyzed with an observation stage analyzing and the present and past situations. Considering the facts, the likely future situations and estimates for the future are developed. The cultural diversity has always been the main concern for any business. So, we have illustrated this through geographical analysis which makes it easy to understand the revenue flow through each region.

For More Research Report Details Visit @https://www.fnfresearch.com/cell-and-gene-therapy-consumables-market-by-product-107

Some of the major objectives of this report:

1) To provide a detailed analysis of the market structure along with the forecast of the various segments and sub-segments of the global Cell and Gene Therapy Consumables market.

2. To provide insights about factors affecting the market growth. To analyze the Cell and Gene Therapy Consumables market based on various factors- price analysis, supply chain analysis, porter five force analyses, etc.

3. To provide historically and forecast revenue of the Cell and Gene Therapy Consumables market segments and sub-segments with respect to four main geographies and their countries- North America, Europe, Asia, and the Rest of the World.

4. Country-level analysis of the market with respect to the current market size and future prospective.

5. To provide country-level analysis of the market for segment by application, product type, and sub-segments.

6. To provide strategic profiling of key players in the market, comprehensively analyzing their core competencies, and drawing a competitive landscape for the market.

7. Track and analyze competitive developments such as joint ventures, strategic alliances, mergers and acquisitions, new product developments, and research and developments in the global Cell and Gene Therapy Consumables market.

The regional segmentation of the Cell and Gene Therapy Consumables market is done as follows:

Competitive Landscape and Cell and Gene Therapy Consumables Market Share Analysis

Cell and Gene Therapy Consumables competitive landscape provides details by vendors, including company overview, company total revenue (financials), market potential, global presence, Cell and Gene Therapy Consumables sales and revenue generated, market share, price, production sites and facilities, SWOT analysis, product launch. For the period 2019-2027, this study provides the Cell and Gene Therapy Consumables sales, revenue, and market share for each player covered in this report.

About Us:

Facts & Factors is a leading market research organization offering industry expertise and scrupulous consulting services to clients for their business development. The reports and services offered by Facts and Factors are used by prestigious academic institutions, start-ups, and companies globally to measure and understand the changing international and regional business backgrounds. Our clients/customers conviction on our solutions and services has pushed us in delivering always the best. Our advanced research solutions have helped them in appropriate decision-making and guidance for strategies to expand their business.

Contact Us:

Facts & Factors

Global Headquarters

Level 8, International Finance Center, Tower 2,

8 Century Avenue, Shanghai,

Postal 200120, China

Tel: +86 21 80360450

Email:sales@fnfresearch.com

Web:https://www.fnfresearch.com

More here:
Size & Share of Cell and Gene Therapy Consumables Market 2020 Research Report and Forecast to 2026 - Surfacing Magazine

Recommendation and review posted by Bethany Smith

New York, June 05, 2020 (GLOBE NEWSWIRE) -- Reportlinker.com announces the release of the report "Bioreactors Market Forecast to 2027 - COVID-19 Impact and Global Analysis by Cell ; Molecule ; Technology ; End User, and Geography" - https://www.reportlinker.com/p05908638/?utm_source=GNW

A bioreactor is equipment or system engineered to provide biologically active environment for the production of various medical and pharmaceutical compounds.The vessel is used to carry out a chemical process, which involves organisms or biochemically active substances derived from such organisms.

This process can either be aerobic or anaerobic.The bioreactors are commonly cylindrical, ranging in size from liters to cubic meters, and are generally made of stainless steel.

Bioreactors provide a controllable environment, in terms of pH, temperature, nutrient supply, and shear stress for any cells.The use of single-use bioreactors has increased in the modern biopharmaceutical processes in the last few years.This can be attributed to their unique ability to allow enhanced process flexibility, reduce investment requirements, and limit operational costs.

Also, many companies have developed single-use bioreactors for the production of a wide range of therapeutics. For instance, Distek Inc., has developed a benchtop single-use bioreactor system for recombinant protein production. Single-use bioreactors reduce the risks of contamination and decrease production turnaround times. Moreover, the reduction in validation time has been one of the prime benefits of single-use bioreactors. The rising adoption of single-use bioreactors for upstream bioprocessing is driving the growth of the market. For instance, Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL microbioreactor scale and Biostat STR for 50-2000 L.The global bioreactors market is segmented on the basis of cell, molecule, technology, and end user.The bioreactors market, by molecule, is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and others.

The monoclonal antibodies segment held the largest share of the market in 2019.However, the stem cell segment is projected to register the highest CAGR in the market during the forecast period.

Based on cell, the bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and others.Based on technology, the market is segmented into wave-induced motion sub, stirred sub, single-use bubble column, and others.

Based on end user, the market is segmented into research and development organizations, biopharma manufacturers, contract manufacturing organizations (CMOs).A few of the essential primary and secondary sources referred to while preparing the report are the Food and Drug Administration (FDA), World Health Organization (WHO), Organization for Economic Co-operation and Development, National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC), among others.Bioreactors Market Forecast to 2027 - Covid-19 Impact and Global Analysis by Cell, Molecule, Technology, End User, and GeographyThe bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a CAGR of 7.3% from 2020 to 2027. A bioreactor is equipment or system engineered to provide biologically active environment for the production of various medical and pharmaceutical compounds.The vessel is used to carry out a chemical process, which involves organisms or biochemically active substances derived from such organisms.

This process can either be aerobic or anaerobic.The bioreactors are commonly cylindrical, ranging in size from liters to cubic meters, and are generally made of stainless steel.

Bioreactors provide a controllable environment, in terms of pH, temperature, nutrient supply, and shear stress for any cells.The use of single-use bioreactors has increased in the modern biopharmaceutical processes in the last few years.This can be attributed to their unique ability to allow enhanced process flexibility, reduce investment requirements, and limit operational costs.

Also, many companies have developed single-use bioreactors for the production of a wide range of therapeutics. For instance, Distek Inc., has developed a benchtop single-use bioreactor system for recombinant protein production. Single-use bioreactors reduce the risks of contamination and decrease production turnaround times. Moreover, the reduction in validation time has been one of the prime benefits of single-use bioreactors. The rising adoption of single-use bioreactors for upstream bioprocessing is driving the growth of the market. For instance, Sartorius AG offers a wide range of single-use bioreactors. The company provides ambr 15 for a 10-15 mL microbioreactor scale and Biostat STR for 50-2000 L.The global bioreactors market is segmented on the basis of cell, molecule, technology, and end user.The bioreactors market, by molecule, is segmented into monoclonal antibodies, vaccines, recombinant proteins, stem cells, gene therapy, and others.

The monoclonal antibodies segment held the largest share of the market in 2019.However, the stem cell segment is projected to register the highest CAGR in the market during the forecast period.

Based on cell, the bioreactors market is segmented into mammalian cells, bacterial cells, yeast cells, and others.Based on technology, the market is segmented into wave-induced motion sub, stirred sub, single-use bubble column, and others.

Based on end user, the market is segmented into research and development organizations, biopharma manufacturers, contract manufacturing organizations (CMOs).A few of the essential primary and secondary sources referred to while preparing the report are the Food and Drug Administration (FDA), World Health Organization (WHO), Organization for Economic Co-operation and Development, National Institutes of Health (NIH), and Centers for Disease Control and Prevention (CDC), among others.Read the full report: https://www.reportlinker.com/p05908638/?utm_source=GNW

About ReportlinkerReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________

More here:
The bioreactors market was valued at US$ 2,958.50 million in 2019 and is projected to reach US$ 5,169.01 million by 2027; it is expected to grow at a...

Recommendation and review posted by Bethany Smith

UpMarketResearch report titled Global Cancer Gene Therapy Market provides detailed information and overview about the key influential factors required to make well informed business decision. This is a latest report, covering the current COVID-19 impact on the market. The pandemic of Coronavirus (COVID-19) has affected every aspect of life globally. This has brought along several changes in market conditions. The rapidly changing market scenario and initial and future assessment of the impact is covered in the report. Our data has been culled out by our team of experts who have curated the report, considering market-relevant information. This report provides latest insights about the markets drivers, restraints, opportunities, and trends. It also discusses the growth and trends of various segments and the market in various regions.

Request Free Sample Report of Cancer Gene Therapy Market Report @ https://www.upmarketresearch.com/home/requested_sample/42057

Cancer Gene Therapy Market Report Includes:

For More Information on This Report Visit @ https://www.upmarketresearch.com/home/enquiry_before_buying/42057

By Product Types:Insertion of new genes into the bodyOther

The report is further broken down into various segments such as product types, applications, and regions.

By Applications:HospitalsDiagnostic CentresDrug ManufacturersResearch Institutes

Our analysts drafted the report by gathering information through primary (through surveys and interviews) and secondary (included industry body databases, reputable paid sources, and trade journals) methods of data collection. The report encompasses an exhaustive qualitative and quantitative evaluation.

The study includes growth trends, micro- and macro-economic indicators, and regulations and governmental policies.

By Regions:Asia Pacific (China, Japan, India, and Rest of Asia Pacific)Europe (Germany, the UK, France, and Rest of Europe)North America (the US, Mexico, and Canada)Latin America (Brazil and Rest of Latin America)Middle East & Africa (GCC Countries and Rest of Middle East & Africa)

The Cancer Gene Therapy Market Report Covers the Following Companies:Cell GenesysAdvantageneGenVecBioCancellCelgene and Epeius BiotechnologiesIntrogen TherapeuticsZIOPHARM OncologyMultiVirShenzhen SiBiono GeneTech

The subject matter experts analyzed various companies to understand the products and/services relevant to the market. The report includes information such as gross revenue, production and consumption, average product price, and market shares of key players. Other factors such as competitive analysis and trends, mergers & acquisitions, and expansion strategies have been included in the report. This will enable the existing competitors and new entrants understand the competitive scenario to plan future strategies.

To Purchase This Report: https://www.upmarketresearch.com/buy/cancer-gene-therapy-market-research

The Report Provides:

The Cancer Gene Therapy Market Report Addresses the Following Queries:

For Best Discount on Purchasing this Report Visit https://www.upmarketresearch.com/home/request_for_discount/42057

About UpMarketResearch:UpMarketResearch (https://www.upmarketresearch.com) is a leading distributor of market research report with more than 800+ global clients. As a market research company, we take pride in equipping our clients with insights and data that holds the power to truly make a difference to their business. Our mission is singular and well-defined we want to help our clients envisage their business environment so that they are able to make informed, strategic and therefore successful decisions for themselves.Contact Info UpMarketResearchName Alex MathewsEmail [emailprotected]Website https://www.upmarketresearch.comAddress 500 East E Street, Ontario, CA 91764, United States.

Continued here:
Cancer Gene Therapy Market Incredible Possibilities, Growth With Industry Study, Detailed Analysis And Forecast To 2025 - Bulletin Line

Recommendation and review posted by Bethany Smith

Global Gene Therapy for Age-related Macular Degeneration Market Report is a professional and in-depth research report on the worlds major regional market. The Gene Therapy for Age-related Macular Degeneration industry2020 by Industry Demand, Business Strategy & Emerging Trends by Leading Players. The Global pandemic of COVID19/CORONA Virus calls for redefining of business strategies. This Gene Therapy for Age-related Macular Degeneration Market report includes the impact analysis necessary for the same.

Download the Sample ToC to understand the CORONA Virus/COVID19 impact and be smart in redefining business strategies. https://inforgrowth.com/CovidImpact-Request/6321856/gene-therapy-for-age-related-macular-degeneration-

Top Players Listed in the Gene Therapy for Age-related Macular Degeneration Market Report areRetroSense Therapeutics, REGENXBIO, AGTC, .

Gene Therapy for Age-related Macular Degenerationmarket report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, the impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.

Market Segmentations: Global Gene Therapy for Age-related Macular Degeneration market competition by top manufacturers, with production, price, revenue (value) and market share for each manufacturer.

Based on type, report split into Subretinal, Intravitreal, Unspecified.

Based on the end users/applications, this report focuses on the status and outlook for major applications/end users, consumption (sales), market share and growth rate for each application, including Monotherapy, Combination Therapy.

Get Exclusive Sample of Report on Gene Therapy for Age-related Macular Degeneration market is available at https://inforgrowth.com/sample-request/6321856/gene-therapy-for-age-related-macular-degeneration-

The report introduces Gene Therapy for Age-related Macular Degeneration basic information including definition, classification, application, industry chain structure, industry overview, policy analysis, and news analysis. Insightful predictions for the Gene Therapy for Age-related Macular Degeneration Market for the coming few years have also been included in the report.

In the end, Gene Therapy for Age-related Macular Degenerationreport provides details of competitive developments such as expansions, agreements, new product launches, and acquisitions in the market for forecasting, regional demand, and supply factor, investment, market dynamics including technical scenario, consumer behavior, and end-use industry trends and dynamics, capacity, spending were taken into consideration.

Important Key questions answered in Gene Therapy for Age-related Macular Degenerationmarket report:

Get Special Discount Up To 50%, https://inforgrowth.com/discount/6321856/gene-therapy-for-age-related-macular-degeneration-

FOR ALL YOUR RESEARCH NEEDS, REACH OUT TO US AT:Address: 6400 Village Pkwy suite # 104, Dublin, CA 94568, USAContact Name: Rohan S.Email:[emailprotected]Phone: +1-909-329-2808UK: +44 (203) 743 1898Website: http://www.inforgrowth.com

More:
Gene Therapy for Age-related Macular Degeneration Market 2020: Potential growth, attractive valuation make it is a long-term investment | Know the...

Recommendation and review posted by Bethany Smith

The global gene therapy market was valued at $584 million in 2016, and is estimated to reach $4,402 million by 2023, registering a CAGR of 33.3% from 2017 to 2023. Gene therapy is a technique that involves the delivery of nucleic acid polymers into a patients cells as a drug to treat diseases. It fixes a genetic problem at its source. The process involves modifying the protein either to change the genetic expression or to correct a mutation. The emergence of this technology meets the rise in needs for better diagnostics and targeted therapy tools. For instance, genetic engineering can be used to modify physical appearance, metabolism, physical capabilities, and mental abilities such as memory and intelligence. In addition, it is also used for infertility treatment. Gene therapy offers a ray of hope for patients, who either have no treatment options or show no benefits with drugs currently available. The ongoing success has strongly supported upcoming researches and has carved ways for enhancement of gene therapy.

Top Companies Covered in this Report:, Novartis, Kite Pharma, Inc., GlaxoSmithKline PLC, Spark Therapeutics Inc., Bluebird bio Inc., Genethon, Transgene SA, Applied Genetic Technologies Corporation, Oxford BioMedica, NewLink Genetics Corp.

Get sample copy of Report at: https://www.premiummarketinsights.com/sample/AMR00013704

The gene therapy market is a widely expanding field in the pharmaceutical industry with new opportunities. This has piqued the interests of venture capitalists to explore this market and its commercial potential. Major factors that drive the growth of this market include high demands for DNA vaccines to treat genetic diseases, targeted drug delivery, and high incidence of genetic disorders. However, the stringent regulatory approval process for gene therapy and the high costs of gene therapy drugs are expected to hinder the growth of the market.

The global gene therapy market is segmented based on vector type, gene type, application, and geography. Based on vector type, it is categorized into viral vector and non-viral vector. Viral vector is further segmented into retroviruses, lentiviruses, adenoviruses, adeno associated virus, herpes simplex virus, poxvirus, vaccinia virus, and others. Non-viral vector is further categorized into naked/plasmid vectors, gene gun, electroporation, lipofection, and others. Based on gene type, the market is classified into antigen, cytokine, tumor suppressor, suicide, deficiency, growth factors, receptors, and others. Based on application, the market is divided into oncological disorders, rare diseases, cardiovascular diseases, neurological disorders, infectious disease, and other diseases. Based on region, it is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Get Discount for This Report https://www.premiummarketinsights.com/discount/AMR00013704

Table Of Content

CHAPTER 1: INTRODUCTION

CHAPTER 2: EXECUTIVE SUMMARY

CHAPTER 3: MARKET OVERVIEW

CHAPTER 4: GENE THERAPY MARKET, BY VECTOR TYPE

CHAPTER 5: GENE THERAPY MARKET, BY GENE TYPE

CHAPTER 6: GENE THERAPY MARKET, BY APPLICATION

CHAPTER 7: GENE THERAPY MARKET, BY REGION

CHAPTER 8: COMPANY PROFILE

Enquire about report at: https://www.premiummarketinsights.com/buy/AMR00013704

About Premium Market Insights:

Premiummarketinsights.com is a one stop shop of market research reports and solutions to various companies across the globe. We help our clients in their decision support system by helping them choose most relevant and cost effective research reports and solutions from various publishers. We provide best in class customer service and our customer support team is always available to help you on your research queries.

Contact Us

Sameer Joshi

Call: +912067274191

Email:[emailprotected]

Pune

Read the original:
Gene Therapy Market to Reach $4402 million by 2023 with Key Players Novartis, Kite Pharma, GlaxoSmithKline, Spark Therapeutics - Cole of Duty

Recommendation and review posted by Bethany Smith

The Viral Vectors And Plasmid DNA Manufacturing market has witnessed growth from USD XX million to USD XX million from 2014 to 2019. With the CAGR of X.X%, this market is estimated to reach USD XX million in 2026.

The report mainly studies the size, recent trends and development status of the Viral Vectors And Plasmid Dna Manufacturing market, as well as investment opportunities, government policy, market dynamics (drivers, restraints, opportunities), supply chain and competitive landscape. Technological innovation and advancement will further optimize the performance of the product, making it more widely used in downstream applications. Moreover, Porters Five Forces Analysis (potential entrants, suppliers, substitutes, buyers, industry competitors) provides crucial information for knowing the Viral Vectors And Plasmid Dna Manufacturing market.

Download PDF Sample of Viral Vectors And Plasmid Dna Manufacturing Market report @ https://www.arcognizance.com/enquiry-sample/1006415

Major Players in the global Viral Vectors And Plasmid Dna Manufacturing market include:, Sanofi, Lonza, FinVector, Oxford BioMedica, BioVector NTCC, FUJIFILM Diosynth Biotechnologies, MassBiologics, NTC, Waisman Biomanufacturing, Addgene, Invivogen, ATCC, NBRP, OriGene, Brammer Bio, Cobra Biologics, BioReliance, DSMZ, MolMed, Biovian

On the basis of types, the Viral Vectors And Plasmid Dna Manufacturing market is primarily split into:, Viral Vectors, Plasmid DNA

On the basis of applications, the market covers:, Gene Therapy, Vaccination, Immunotherapy, Formulation development, Others

Brief about Viral Vectors And Plasmid Dna Manufacturing Market Report with [emailprotected] https://www.arcognizance.com/report/global-viral-vectors-and-plasmid-dna-manufacturing-market-report-2019-competitive-landscape-trends-and-opportunities

Geographically, the report includes the research on production, consumption, revenue, market share and growth rate, and forecast (2014-2026) of the following regions:, United States, Europe (Germany, UK, France, Italy, Spain, Russia, Poland), China, Japan, India , Southeast Asia (Malaysia, Singapore, Philippines, Indonesia, Thailand, Vietnam), Central and South America (Brazil, Mexico, Colombia), Middle East and Africa (Saudi Arabia, United Arab Emirates, Turkey, Egypt, South Africa, Nigeria), Other Regions

Chapter 1 provides an overview of Viral Vectors And Plasmid Dna Manufacturing market, containing global revenue, global production, sales, and CAGR. The forecast and analysis of Viral Vectors And Plasmid Dna Manufacturing market by type, application, and region are also presented in this chapter.

Chapter 2 is about the market landscape and major players. It provides competitive situation and market concentration status along with the basic information of these players.

Chapter 3 provides a full-scale analysis of major players in Viral Vectors And Plasmid Dna Manufacturing industry. The basic information, as well as the profiles, applications and specifications of products market performance along with Business Overview are offered.

Chapter 4 gives a worldwide view of Viral Vectors And Plasmid Dna Manufacturing market. It includes production, market share revenue, price, and the growth rate by type.

Chapter 5 focuses on the application of Viral Vectors And Plasmid Dna Manufacturing, by analyzing the consumption and its growth rate of each application.

Chapter 6 is about production, consumption, export, and import of Viral Vectors And Plasmid Dna Manufacturing in each region.

Chapter 7 pays attention to the production, revenue, price and gross margin of Viral Vectors And Plasmid Dna Manufacturing in markets of different regions. The analysis on production, revenue, price and gross margin of the global market is covered in this part.

Chapter 8 concentrates on manufacturing analysis, including key raw material analysis, cost structure analysis and process analysis, making up a comprehensive analysis of manufacturing cost.

Chapter 9 introduces the industrial chain of Viral Vectors And Plasmid Dna Manufacturing. Industrial chain analysis, raw material sources and downstream buyers are analyzed in this chapter.

Chapter 10 provides clear insights into market dynamics.

Chapter 11 prospects the whole Viral Vectors And Plasmid Dna Manufacturing market, including the global production and revenue forecast, regional forecast. It also foresees the Viral Vectors And Plasmid Dna Manufacturing market by type and application.

Chapter 12 concludes the research findings and refines all the highlights of the study.

Chapter 13 introduces the research methodology and sources of research data for your understanding.

Years considered for this report:, Historical Years: 2014-2018, Base Year: 2019, Estimated Year: 2019, Forecast Period: 2019-2026,

Some Point of Table of Content:

Chapter One: Viral Vectors And Plasmid Dna Manufacturing Market Overview

Chapter Two: Global Viral Vectors And Plasmid Dna Manufacturing Market Landscape by Player

Chapter Three: Players Profiles

Chapter Four: Global Viral Vectors And Plasmid Dna Manufacturing Production, Revenue (Value), Price Trend by Type

Chapter Five: Global Viral Vectors And Plasmid Dna Manufacturing Market Analysis by Application

Chapter Six: Global Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import by Region (2014-2019)

Chapter Seven: Global Viral Vectors And Plasmid Dna Manufacturing Production, Revenue (Value) by Region (2014-2019)

Chapter Eight: Viral Vectors And Plasmid Dna Manufacturing Manufacturing Analysis

Chapter Nine: Industrial Chain, Sourcing Strategy and Downstream Buyers

Chapter Ten: Market Dynamics

Chapter Eleven: Global Viral Vectors And Plasmid Dna Manufacturing Market Forecast (2019-2026)

Chapter Twelve: Research Findings and Conclusion

Chapter Thirteen: Appendix continued

List of tablesList of Tables and Figures

Figure Viral Vectors And Plasmid Dna Manufacturing Product PictureTable Global Viral Vectors And Plasmid Dna Manufacturing Production and CAGR (%) Comparison by TypeTable Profile of Viral VectorsTable Profile of Plasmid DNATable Viral Vectors And Plasmid Dna Manufacturing Consumption (Sales) Comparison by Application (2014-2026)Table Profile of Gene TherapyTable Profile of VaccinationTable Profile of ImmunotherapyTable Profile of Formulation developmentTable Profile of OthersFigure Global Viral Vectors And Plasmid Dna Manufacturing Market Size (Value) and CAGR (%) (2014-2026)Figure United States Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Europe Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Germany Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure UK Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure France Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Italy Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Spain Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Russia Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Poland Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure China Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Japan Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure India Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Southeast Asia Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Malaysia Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Singapore Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Philippines Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Indonesia Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Thailand Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Vietnam Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Central and South America Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Brazil Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Mexico Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Colombia Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Middle East and Africa Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Saudi Arabia Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure United Arab Emirates Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Turkey Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Egypt Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure South Africa Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Nigeria Viral Vectors And Plasmid Dna Manufacturing Revenue and Growth Rate (2014-2026)Figure Global Viral Vectors And Plasmid Dna Manufacturing Production Status and Outlook (2014-2026)Table Global Viral Vectors And Plasmid Dna Manufacturing Production by Player (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Production Share by Player (2014-2019)Figure Global Viral Vectors And Plasmid Dna Manufacturing Production Share by Player in 2018Table Viral Vectors And Plasmid Dna Manufacturing Revenue by Player (2014-2019)Table Viral Vectors And Plasmid Dna Manufacturing Revenue Market Share by Player (2014-2019)Table Viral Vectors And Plasmid Dna Manufacturing Price by Player (2014-2019)Table Viral Vectors And Plasmid Dna Manufacturing Manufacturing Base Distribution and Sales Area by PlayerTable Viral Vectors And Plasmid Dna Manufacturing Product Type by PlayerTable Mergers & Acquisitions, Expansion PlansTable Sanofi ProfileTable Sanofi Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Lonza ProfileTable Lonza Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table FinVector ProfileTable FinVector Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Oxford BioMedica ProfileTable Oxford BioMedica Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table BioVector NTCC ProfileTable BioVector NTCC Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table FUJIFILM Diosynth Biotechnologies ProfileTable FUJIFILM Diosynth Biotechnologies Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table MassBiologics ProfileTable MassBiologics Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table NTC ProfileTable NTC Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Waisman Biomanufacturing ProfileTable Waisman Biomanufacturing Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Addgene ProfileTable Addgene Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Invivogen ProfileTable Invivogen Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table ATCC ProfileTable ATCC Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table NBRP ProfileTable NBRP Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table OriGene ProfileTable OriGene Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Brammer Bio ProfileTable Brammer Bio Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Cobra Biologics ProfileTable Cobra Biologics Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table BioReliance ProfileTable BioReliance Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table DSMZ ProfileTable DSMZ Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table MolMed ProfileTable MolMed Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Biovian ProfileTable Biovian Viral Vectors And Plasmid Dna Manufacturing Production, Revenue, Price and Gross Margin (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Production by Type (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Production Market Share by Type (2014-2019)Figure Global Viral Vectors And Plasmid Dna Manufacturing Production Market Share by Type in 2018Table Global Viral Vectors And Plasmid Dna Manufacturing Revenue by Type (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Revenue Market Share by Type (2014-2019)Figure Global Viral Vectors And Plasmid Dna Manufacturing Revenue Market Share by Type in 2018Table Viral Vectors And Plasmid Dna Manufacturing Price by Type (2014-2019)Figure Global Viral Vectors And Plasmid Dna Manufacturing Production Growth Rate of Viral Vectors (2014-2019)Figure Global Viral Vectors And Plasmid Dna Manufacturing Production Growth Rate of Plasmid DNA (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption by Application (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption Market Share by Application (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption of Gene Therapy (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption of Vaccination (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption of Immunotherapy (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption of Formulation development (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption of Others (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption by Region (2014-2019)Table Global Viral Vectors And Plasmid Dna Manufacturing Consumption Market Share by Region (2014-2019)Table United States Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)Table Europe Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)Table China Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)Table Japan Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)Table India Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)Table Southeast Asia Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)Table Central and South America Viral Vectors And Plasmid Dna Manufacturing Production, Consumption, Export, Import (2014-2019)continued

If you have any special requirements, please let us know and we will offer you the report as you want.

About Us:Analytical Research Cognizance (ARC)is a trusted hub for research reports that critically renders accurate and statistical data for your business growth. Our extensive database of examined market reports places us amongst the best industry report firms. Our professionally equipped team further strengthens ARCs potential.ARC works with the mission of creating a platform where marketers can have access to informative, latest and well researched reports. To achieve this aim our experts tactically scrutinize every report that comes under their eye.

Contact Us:Ranjeet DengaleDirector SalesAnalytical Research Cognizance+1 (646) 403-4695, +91 90967 44448Email: [emailprotected]

NOTE: Our report does take into account the impact of coronavirus pandemic and dedicates qualitative as well as quantitative sections of information within the report that emphasizes the impact of COVID-19.

As this pandemic is ongoing and leading to dynamic shifts in stocks and businesses worldwide, we take into account the current condition and forecast the market data taking into consideration the micro and macroeconomic factors that will be affected by the pandemic.

See more here:
Viral Vectors And Plasmid DNA Manufacturing Market by Manufacturers, Regions, Type and Application, Forecast to 2026 - Cole of Duty

Recommendation and review posted by Bethany Smith

The Juvenile Macular Degeneration (Stargardt Disease) Treatment Market report upholds the future market predictions related to Juvenile Macular Degeneration (Stargardt Disease) Treatment market size, revenue, production, Consumption, gross margin and other substantial factors. It also examines the role of the prominent Juvenile Macular Degeneration (Stargardt Disease) Treatment market players involved in the industry including their corporate overview. While emphasizing the key driving factors for Juvenile Macular Degeneration (Stargardt Disease) Treatment market, the report also offers a full study of the future trends and developments of the market.

The analysis on Juvenile Macular Degeneration (Stargardt Disease) Treatment Market presents a realistic assessment of the current market situation, including the Juvenile Macular Degeneration (Stargardt Disease) Treatment market size with regards to the volume and renumeration. The Juvenile Macular Degeneration (Stargardt Disease) Treatment market report has been prepared based on the synthesis, analysis, and clarification of information about the global Juvenile Macular Degeneration (Stargardt Disease) Treatment market from dedicated sources. The report is a collection of significant data related to the competitive landscape of the industry.

Request Sample Copy of this Report @ https://www.express-journal.com/request-sample/105739

Juvenile Macular Degeneration (Stargardt Disease) Treatment market size report mentions the key geographies, market landscapes alongside the product price, revenue, volume, production, supply, demand, market growth rate, and forecast etc. The study offers a thorough assessment of the products manufactured by the firms, specifications, including their application frame of reference.

The Juvenile Macular Degeneration (Stargardt Disease) Treatment market report consist competitive study of the major Juvenile Macular Degeneration (Stargardt Disease) Treatment manufacturerswhich will help to develop a marketing strategy.

Top key playersof industry are covered in Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Research Report:

Synopsis of the competitive landscape

Split by product type,with production, revenue, price, market share and growth rate of each type, can be divided into:

Stem Cell Therapy, Gene Therapy and Others

Split by application,this report focuses on consumption, market share and growth rate of Juvenile Macular Degeneration (Stargardt Disease) Treatment market in each application and can be divided into:

Hospitals, Eye Clinics and Others

An overview of market segmentation

Major Key factors of Juvenile Macular Degeneration (Stargardt Disease) Treatment market is explained in this report are as below:

Request Customization on This Report @ https://www.express-journal.com/request-for-customization/105739

See the rest here:
Juvenile Macular Degeneration (Stargardt Disease) Treatment Market Research, Recent Trends and Growth Forecast 2025 - Express Journal

Recommendation and review posted by Bethany Smith

As the coronavirus pandemic continues to threaten public health, scientists throughout the world have been working around the clock to develop effective treatments against COVID-19. CRISPR gene editing is one of the techniques researchers are using. During the Virtual Regeneron International Science and Engineering Fair (ISEF), Tina Hesman Saey, Senior Writer and molecular biology reporter at Science News, spoke with Feng Zhang (ISEF 1998-1999, STS 2000), one of the pioneers of CRISPR technology, about CRISPRs role in fighting COVID-19.

Feng shared three main ways CRISPR is being used to fight COVID-19:

Students asked whether human genes could be modified as another possible defense against the coronavirus. Before editing the human genome can occur, however, Feng cautioned we must first better understand how the virus works. The idea of engineering CRISPR into our own cells to fight the virus is a ways off, he stated. Wed have to find out more about the way CRISPR proteins behave in the body and how we can use them safely.

Given the scope of the coronavirus pandemic, Feng finds it very encouraging to see scientists, technologists and companies collaborating now more than ever. We are facing one common problem and we need to work together to provide as many solutions as possible, he noted. As some researchers work on a vaccine, others are developing at-home tests to scale up testing capacity. Manufacturers are supporting these efforts by producing more reagents, the chemical compounds tests depend on to deliver results. What is really promising is that all these different aspects are being addressed, he lauded.

The level of teamwork Feng has witnessed within the scientific community during this global crisis reminds him of the same collegiality he encountered as a student. You can strike up conversation with anybody at a science fair, he said. Competing in both STS and ISEF were transformative experiences for Feng. He made many friends that he still interacts with today, even occasionally working on projects with people he met then.

Looking ahead, what can students do to help facilitate research on COVID-19? Reach out to people who are working on things you find interesting, Feng advised. Youll be surprised to find there are many ways you could be engaged and contribute. With epidemiologists analyzing public health data, scientists seeking to gain a molecular understanding of the virus and others studying its origins, just to name a few areas, there is ample opportunity to get involved and make a positive difference.

If you missed this session, it can be viewed in full on our online platform through June 5. Register here.

Visit link:
ICYMI: The role of CRISPR in the fight against COVID-19 - Science News for Students

Recommendation and review posted by Bethany Smith

Conservation biology is plagued by cases of mistaken identity. Salamanders that look exactly the same turn out to live a continent apart. A group of seemingly homogenous eels is actually two different types. New species of fungi hide in plain sight, disguised as ones we know well.

So in 2017, when California Department of Water Resources animal scientist Melinda Baerwald read about a tool that could quickly differentiate between similar viruses and bacteria, I just thought, oh my gosh, she says. The tool, called SHERLOCK, was developed by biochemists, and uses CRISPR technology, which has already revolutionized medical research. Dr. Baerwald thinks it could have a similar effect on conservation biology by enabling fast, low-cost species identification in the lab or in the field. In a new paper in Molecular Ecology Resources, Dr. Baerwald and colleagues describe how they used the technology to build tests that can differentiate between species doppelgngers.

Dr. Baerwald and her colleagues used SHERLOCK to develop two slightly different identity tests. Both rely on CRISPRs ability to recognize particular segments of DNA, which allows the tests to answer yes or no questions: not What kind of bear is this? for example, but rather, Is this a polar bear? The first type of test, which is done in a tube, involves a reagent that fluoresces when it comes into contact with the target DNA, and takes about 20 minutes. The second requires less equipment, and works more like a pregnancy testa positive identification shows up as a band on a test stripbut takes slightly longer, and is a little more expensive.

They then tested the tools on three species of fish: delta smelt, longfin smelt, and wakasagi. All three look quite similar at the larval stagetranslucent and wrigglyand all three live in the San Francisco Estuary, where they are frequently mistaken for one another. (A 2018 study found that 27% of supposed wakasagi sampled during a monitoring survey were actually delta smelt.) But the delta smelt is federally threatened and the longfin smelt is endangered in the state of California, while the wakasagi is an introduced species without any special protections.

After using them on dozens of samples of fish whose species had been determined by other means, the team found the tests achieved 100% species specificity: delta smelts always IDd positively as delta smelts, longfin smelts as longfin smelts, and wakasagi as wakasagi.

They are also easy to use in the field. Currently, if you want a quick and reliable ID result, you generally have to send a sample to a lab, where testing can be expensive and often takes at least a day to complete. Dr. Baerwald says. These tests take less than an hour, and could provide the ability to make close to real-time decisions at a much lower cost, she says.

This will be quite helpful to the Department of Water Resources, which needs to differentiate between these species in order to make sure too many protected fish dont end up pulled into water pumps, Dr. Baerwald says. But she can imagine it proving useful in many other situations, too: to fight wildlife trafficking by quickly IDing rare species, for example, or to make identifications while out in the field.

The team is still working on refining the tests, hoping to provide an option that is quick, inexpensive, easy to use, and non-invasive. Of course, species identification is just the first step in conservationonce you figure out what something is, you still have to work hard to protect it, as evidenced by the fraught story of the delta smelt.

But Dr. Baerwald is excited to see where this innovation leads, and happy that conservation biology can benefit from an advance originally pioneered in a different and better-fundedsphere. You can cross technologies from one field into another, she says. That is a really powerful thing to do.

Image: Envato

See more here:
CRISPR has revolutionized medical research. Will conservation biology be next? - Anthropoce

Recommendation and review posted by Bethany Smith

Fact.MR has adopted a multi-disciplinary approach to shed light on the evolution of the global CRISPR and Cas Genes market during the historical period of 2015 2019. The study presents a deep-dive assessment of the current growth dynamics, major avenues in the estimation year of 2020, and key prospects over the forecast period 2020 2026.The CRISPR and Cas Genes market study includes a thorough analysis of the overall competitive landscape and the company profiles of leading market players involved in the global CRISPR and Cas Genes market. Further, the presented study offers accurate insights pertaining to the different segments of the Global CRISPR and Cas Genes market such as the market share, value, revenue, and how each segment is expected to fair post the COVID-19 pandemic.

The global CRISPR and Cas genes market shows stellar future growth prospects, expanding at a CAGR of 21.2% during the forecast period (2020-2026). Extensive rounds of primary and comprehensive secondary research have been leveraged by the analysts at Fact.MR to arrive at various estimations and projections of the CRISPR and Cas Genes market, both at global and regional levels. The analysts have used numerous industry-wide prominent business intelligence tools to consolidate facts, figures, and market data into revenue estimations and projections in theCRISPR and Cas Genes market.

After reading the CRISPR and Cas Genes market report, readers get insight into:

Request for Sample Report with Statistical Info @https://www.factmr.com/connectus/sample?flag=S&rep_id=4823

The CRISPR and Cas Genes market report offers an assessment of prevailing opportunities in various regions and evaluates their shares of revenue by the end of different years of the assessment period. Key regions covered comprise:

The evaluation of the competitive landscape in the CRISPR and Cas Genes market covers the profile of the following top players:

To expand the understanding of opportunities in the global CRISPR and Cas Genes market report looks at close quarters into the opportunities and new avenues in the following key segments:

In addition to understanding the demand patterns of various end user, the report on the CRISPR and Cas Genes market also enumerates trends expected to attract investments by other various associated industries.

On the basis of Product types, the CRISPR and Cas Genes market report offers insight into major adoption trends for the following segments:

By Application,

The global CRISPR and Cas Genes market report offers detailed assessments and quantitative evaluations that shed light on numerous key aspects that have shaped its evolution over the historical period. In the coming years, some of the key aspects that will shape the growth prospects during the forecast period are objectively covered in the study.

For More Detailed Information about Methodology @https://www.factmr.com/connectus/sample?flag=RM&rep_id=4823

Some important questions that the CRISPR and Cas Genes market report tries to answer exhaustively are:

About Fact.MR

Fact.MR is a fast-growing market research firm that offers the most comprehensive suite of syndicated and customized market research reports. We believe transformative intelligence can educate and inspire businesses to make smarter decisions. We know the limitations of the one-size-fits-all approach; thats why we publish multi-industry global, regional, and country-specific research reports.

Media Release:https://www.factmr.com/media-release/1591/global-crispr-and-cas-genes-market

The rest is here:
Vector-based Systems will Remain Dominant, Accounting for 60% of the Global CRISPR-Cas Genes Market Value - The Cloud Tribune

Recommendation and review posted by Bethany Smith

In May, federal regulators finalized a new biotechnology policy that will bring sweeping changes to the U.S. food system. Dubbed SECURE, the rule revises U.S. Department of Agriculture regulations over genetically engineered plants, automatically exempting many gene-edited crops from government oversight. Companies and labs will be allowed to self-determine whether or not a crop should undergo regulatory review or environmental risk assessment.

Initial responses to this new policy have followed familiar fault lines in the food community. Seed industry trade groups and biotech firms hailed the rule as important to support continuing innovation. Environmental and small farmer NGOs called the USDAs decision shameful and less attentive to public well-being than to agribusinesss bottom line.

But the gene-editing tool CRISPR was supposed to break the impasse in old GM wars by making biotechnology more widely affordable, accessible and thus democratic.

In my research, I study how biotechnology affects transitions to sustainable food systems. Its clear that since 2012 the swelling R&D pipeline of gene-edited grains, fruits and vegetables, fish and livestock has forced U.S. agencies to respond to the so-called CRISPR revolution.

Yet this rule change has a number of people in the food and scientific communities concerned. To me, it reflects the lack of accountability and trust between the public and government agencies setting policies.

The USDA Animal and Plant Health Inspection Service, or APHIS, serves as the dominant U.S. regulator for plant health. Since the mid-1990s, genetically modified crops have typically fallen under APHIS oversight because Agrobacterium, a plant pest, is commonly used as a tool to engineer GM products. Using a plant pest did not prevent many GM crops from being approved. But it did mean that if APHIS suspected a plant pest or noxious weed had been created through genetic engineering, the agency would regulate the biotech product, including its release into the environment, and its import, handling, and interstate movement.

Changes to APHIS regulations began during the Obama administration. In January 2017, the agency released new draft rules. However, the Trump administration withdrew these nine months later after pushback from industry and biotech developers which argued that the rules would stifle innovation.

Last summer, USDA released a revised rule for public comment, which it finalized on May 18, 2020. Most changes go into effect in April 2021.

Hints to how USDA intended to treat gene-edited crops came early on, when Penn States nonbrowning mushrooms and DuPonts waxy corn were approved by APHIS in 2015 and 2016, respectively.

Then in March 2018, USDA Secretary Perdue clarified the agencys stance. USDA does not currently regulate, or have any plans to regulate, plants that could otherwise have been developed through traditional breeding techniques as long as they are developed without the use of a plant pest as the donor or vector and they are not themselves plant pests.

The new SECURE rule establishes several ways for developers to qualify for deregulated status. Included are CRISPR modifications like deletions of sections of the genetic code, tiny substitutions, and introductions of DNA from related species. So, for example, a CRISPRd cauliflower would not be regulated if a chunk of DNA was deleted. But it would still be regulated if CRISPR introduced foreign DNA into cauliflower in a way that USDA believes could turn the product into a plant pest.

Another significant change is that companies and scientists will get to decide for themselves if a new product qualifies for exemption from oversight. APHIS says that developers may consult regulators if at any point they arent sure if a new crop is exempt. However, the agency has already expressed confidence that only about 1% of plants might not qualify for an exemption or for deregulation after an initial review.

Ironically, this policy has begun aligning communities typically at loggerheads in the polarized GM conversation. For example, the UC-based Innovative Genomics Institute, founded by CRISPR co-inventor Jennifer Doudna, wrote in its public comments to APHIS: While we recognize the agencys rationale behind self-determination and desire to provide regulatory relief in order to spur innovation, we are concerned that rather than stimulating innovation, such an undisclosed step may have the effect of dampening trust through the loss of transparency in the development and oversight process.

Meanwhile, GM-watchdog organizations including the National Family Farmers Coalition, Pesticide Action Network and Friends of the Earth issued a joint press statement criticizing a rule that allows industry to self-determine its regulatory status. The new framework, they said, has dealt a devastating blow to the security of farmers livelihoods, the health of their farms and communities, and their ability to build the biodiverse, climate-resilient, and economically robust farming systems that we so urgently need.

My research on democratizing biotechnology has helped me unpack the problematic ways in which democracy is being hitched to technological innovation. When it comes to CRISPR, the public has been told that being cheap, easy to use and free from regulation is a powerful cocktail that makes gene editing intrinsically more democratic.

Like many convenient narratives, there are certain truths to this story. But just as clearly, cheapness is not equivalent to democratic. According to USDA, some 6,150 comments were received on the draft rule during the three-month public feedback period, a window designed to give citizens a say in government policy.

The agency admitted that most letters expressed general opposition to GE products. Of the comments that specifically addressed provisions of the rule, approximately 25 expressed some support for the rule. This means a vast majority of the comments did not. Yet, the USDA disregarded this feedback. Such a lack of civic input can lead to environmental and health concerns being sidelined.

Thoughtful scientists, social movements and governments are now asking if there is an alternative way to regulate engineered food. For example, the Norwegian Biotechnology Advisory Board has set out an ethics-based regulatory framework aimed at advancing genetic technology, while protecting community and environmental health and promoting societal welfare.

In the academic sphere, colleagues in Europe have proposed a framework for responsible innovation. I have developed a set of principles and practices for governing CRISPR based on dialogue with front-line communities who are most affected by the technologies others usher in. Communities dont just have to adopt or refuse technology they can co-create it.

One way to move forward in the U.S. is to take advantage of common ground between sustainable agriculture movements and CRISPR scientists. The struggle over USDA rules suggests that few outside of industry believe self-regulation is fair, wise or scientific.

At present, companies dont even have to notify the USDA of biotech crops they will commercialize. The result, as Greg Jaffe of the Center for Science in the Public Interest told Science, is that government regulators and the public will have no idea what products will enter the market. Farmers and everyone else will pay the price,said Jim Goodman, dairy farmer and board president of the National Family Farm Coalition.

Reclaiming a baseline of accountability, then, is the first step in building public confidence in regulatory systems that work for people as well as science that the public believes in.

[Deep knowledge, daily. Sign up for The Conversations newsletter.]

Link:
How a new biotech rule will foster distrust with the public and impede progress in science - The Conversation US

Recommendation and review posted by Bethany Smith

CAMBRIDGE, Mass., June 05, 2020 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading genome editing company focused on developing curative therapeutics using CRISPR/Cas9 technology bothin vivoandex vivo,today announced the closing of an underwritten public offering of 6,301,370 shares of its common stock, including the exercise in full by the underwriters of their option to purchase an additional 821,917 shares, at the public offering price of $18.25 per share. The gross proceeds raised in the offering, before underwriting discounts and commissions and estimated expenses of the offering, were approximately $115 million.

Goldman Sachs & Co. LLC, Jefferies and SVB Leerink acted as joint book-running managers for the offering.

The shares of common stock were offered by Intellia pursuant to a shelf registration statement that was previously filed with, and subsequently declared effective by, the U.S. Securities and Exchange Commission (SEC). A final prospectus supplement and accompanying prospectus relating to and describing the terms of the offering was filed with the SEC on June 3, 2020. The final prospectus supplement and accompanying prospectus relating to the offering may be obtained from: Goldman Sachs & Co. LLC, by mail at 200 West Street, New York, NY 10282, Attention: Prospectus Department, by telephone at (866) 471-2526, or by email at prospectus-ny@ny.email.gs.com; or Jefferies LLC, by mail at 520 Madison Avenue, 2nd Floor, New York, NY 10022, Attention: Equity Syndicate Prospectus Department, by telephone at (877) 547-6340, or by email at Prospectus_Department@Jefferies.com; or SVB Leerink LLC, by mail at One Federal Street, 37th Floor, Boston, MA 02110, Attention: Syndicate Department, by telephone at (800) 808-7525, ext. 6218, or by email at syndicate@svbleerink.com; or by accessing the SECs website at http://www.sec.gov.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Intellia Therapeutics

Intellia Therapeuticsis a leading genome editing company focused on developing proprietary, curative therapeutics using the CRISPR/Cas9 system.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, as amended, including, without limitation, statements regarding Intellias anticipated public offering. The words may, will, could, would, should, expect, plan, anticipate, intend, believe, estimate, predict, project, potential, continue, target and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. Any forward-looking statements in this press release are based on management's current expectations and beliefs and are subject to a number of risks, uncertainties and important factors that may cause actual events or results to differ materially from those expressed or implied by any forward-looking statements contained in this press release, including, without limitation, uncertainties related to market conditions. These and other risks and uncertainties are described in greater detail in the section entitled Risk Factors in Intellias most recent annual report on Form 10-K and quarterly report on Form 10-Q filed with the SEC, as well as discussions of potential risks, uncertainties, and other important factors in Intellias other filings with the SEC, including those contained or incorporated by reference in the final prospectus supplement and accompanying prospectus related to the public offering filed with the SEC. Any forward-looking statements contained in this press release represent Intellias views only as of the date hereof and should not be relied upon as representing its views as of any subsequent date. Intellia explicitly disclaims any obligation to update any forward-looking statements, except as required by law.

Intellia Contacts:

Investors:Lina LiAssociate DirectorInvestor Relations+1 857-706-1612lina.li@intelliatx.com

Media:Jennifer Mound SmoterSenior Vice PresidentExternal Affairs & Communications+1 857-706-1071jenn.smoter@intelliatx.com

Link:
Intellia Therapeutics Announces Closing of $115 Million Public Offering of Common Stock, Including Full Exercise of Underwriters' Option to Purchase...

Recommendation and review posted by Bethany Smith